Примечания
1
Алиса Витти. В своем ритме. Уникальный метод синхронизации с циклом, который изменит вашу жизнь за 28 дней. – Эксмо, 2021.
2
Howard Schneider et al., “Conventional SPECT Versus 3D Thresholded SPECT Imaging in the Diagnosis of ADHD: A Retrospective Study,” Journal of Neuropsychiatry and Clinical Neurosciences 26, no. 4 (Fall 2014): 335-43 J. F. Thornton et al., “Improved Outcomes Using Brain SPECT-Guided Treatment Versus Treatment-as-Usual in Community Psychiatric Outpatients: A Retrospective CaseControl Study,” Journal of Neuropsychiatry and Clinical Neuroscience 26, no. 1 (Winter 2014): 51–56.
3
NPR Staff, “The Thomas Eagleton Affair Haunts Candidates Today,” NPR, August 4, 2012, www.npr.org/2012/08/04/157670201/the-thomas-eagleton-affair-haunts-candidates-today.
4
Joshua Wolf Shenk, “Lincoln’s Great Depression,” Atlantic, October 2005, www.theatlantic.com/magazine/archive/2005/10/lincolns-great-depression/304247/.
5
Edward J. Kempf, “Abraham Lincoln’s Organic and Emotional Neurosis,” A.M.A. Archives of Neurology and Psychiatry 67, no. 4 (April 1952): 419-33; accessed at www.lincolnportrait.com/emotional_neurosis.html. Timothy P. Townsend, “Life of Lincoln, 1809–1865,” National Park Service, US Department of the Interior, https://www.nps.gov/liho/learn/historyculture/life.htm.
6
National Institute of Mental Health, “Suicide,” updated April 2019, www.nimh.nih.gov/health/statistics/suicide.shtml.
7
Holly Hedegaard, Sally C. Curtin, and Margaret Warner, “Suicide Mortality in the United States, 1999–2017,” National Center for Health Statistics Data Brief no. 330, November 2018, www.cdc.gov/nchs/products/databriefs/db330.htm.
8
Jürgen Unützer, “What If We Treated Mental Health Like Cancer?” NEJM Catalyst event, “Expanding the Bounds of Care Delivery: Integrating Mental, Social, and Physical Health,” January 25, 2018, Vanderbilt University Medical Center, catalyst.nejm.org/videos/treat-mental-health-like-cancer/.
9
Lawrence Scholl et al., “Drug and Opioid-Involved Overdose Deaths – United States, 2013–2017,” Morbidity and Mortality Weekly Report, Centers for Disease Control and Prevention, January 4, 2019, www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm?s_cid=mm675152e1_w.
10
J. M. Twenge et al., “Age, Period, and Cohort Trends in Mood Disorder Indicators and Suicide-Related Outcomes in a Nationally Representative Dataset, 2005–2017,” Journal of Abnormal Psychology 128, no. 3 (April 2019): 185-99
11
J. Breslau J et al., “Sex Differences in Recent First-Onset Depression in an Epidemiological Sample of Adolescents,” Translational Psychiatry 7 (2017): 1139.
12
Janice Wood, “Antidepressant Use Up 400 Percent in US,” Psych Central, January 8, 2018, psychcentral.com/news/2011/10/25/antidepressant-use-up-400-percent-in-us/30677.html.
13
R. C. Kessler, M. Angermeyer, J. C. Anthony et al. “Lifetime Prevalence and Age-of-Onset Distributions of Mental Disorders in the World Health Organization’s World Mental Health Survey Initiative,” World Psychiatry 6 no. 3 (October 2007): 168-76, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174588/. “Learn about Mental Health,” Centers for Disease Control and Prevention, January 26, 2018, https://www.cdc.gov/mentalhealth/learn/.
14
Jürgen Unützer, “What If We Treated Mental Health Like Cancer?” NEJM Catalyst, January 25, 2018, https://catalyst.nejm.org/videos/treat-mental-health-like-cancer/. K. Kroenke and J. Unützer, “Closing the False Divide: Sustainable Approaches to Integrating Mental Health Services into Primary Care,” Journal of General Internal Medicine 32, no. 4 (2017): 404-10
15
Julia Velten et al., “Lifestyle Choices and Mental Health: A Representative Population Survey,” BMC Psychology 2, no. 58 (2014): 58.
16
Mitsutaka Takada, Mai Fujimoto, Kouichi Hosomi, “Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases,” International Journal of Medical Sciences 13, no. 11 (October 18, 2016): 825-34.
17
Запрещен в России.
18
Thomas R. Insel, “Disruptive Insights in Psychiatry: Transforming a Clinical Discipline,” Journal of Clinical Investigation 119, no. 4 (April 1, 2009): 700–705.I. Kirsch, “Antidepressants and the Placebo Response,” Epidemiologia e Psichiatria Sociale 18, no. 4 (October – December 2009): 318-22.
19
Steven E. Hyman, “The Daunting Polygenicity of Mental Illness: Making a New Map,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 373, no. 1742 (March 19, 2018): 20170031.
20
Kate Allsopp et al., “Heterogeneity in Psychiatric Diagnostic Classification,” Psychiatry Research 279 (September 2019): 15–22.
21
Там же.
22
Daniel G. Amen et al., “Multi-Site, Six Month Outcome Study of Complex Psychiatric Patients Evaluated with Addition of Brain SPECT Imaging,” Advances in Mind-Body Medicine 27, no. 2 (January 1996): 6-16.
23
John Green, “What Is the Origin of the Word ‘Shrink’ for Psychologists?” Classroom, last modified July 31, 2019, https://classroom.synonym.com/origin-word-shrink-psychologists11814.html.
24
Daniel G. Amen et al., “Predicting Positive and Negative Treatment Responses to Stimulants with Brain SPECT Imaging,” Journal of Psychoactive Drugs 40, no. 2 (June 2008): 131-38.
25
“Psychiatry,” Dictionary.com, https://www.dictionary.com/browse/psychiatry.
26
Richard Restak, Mysteries of the Mind (National Geographic Society, 2000).
27
Christos F. Kleisiaris et al., “Health Care Practices in Ancient Greece: The Hippocratic Ideal,” Journal of Medical Ethics and History of Medicine 7, no. 6 (March 15, 2014).
28
Hippocrates, The Genuine Works of Hippocrates (New York: W. Wood and Company, 1886).
29
Kleisiaris et al., “Health Care Practices in Ancient Greece: The Hippocratic Ideal.”
30
R. J. Hankinson, “Galen’s Anatomy of the Soul,” Phronesis 36, no. 2 (1991): 197–233.
31
D. Brett King, William Douglas Woody, and Wayne Viney, A History of Psychology: Ideas and Context (New York: Routledge, 2013), 72.
32
Ingrid G. Farreras, “History of Mental Illness,” в R. Biswas-Diener and E. Diener, eds. Noba Textbook Series: Psychology (Champaign, IL: DEF Publishers), см. http://noba.to /65w3s7ex.
33
Theodore Porter, Genetics in the Madhouse (Princeton, NJ: Princeton University Press, 2018).
34
Alexandra Minna Stern, “That Time the United States Sterilized 60,000 of Its Citizens,” Huffington Post, January 7, 2016, www.huffingtonpost.com/entry/sterilization-united-states_us_568f35f2e4b0c8beacf68713.
35
Farreras, “History of Mental Illness.”
36
Joshua Wolf Shenk, Lincoln’s Melancholy (New York: Houghton Mifflin, 2005), 58.
37
Melissa Fares, “Michael Phelps’ Purple Blotches Spotlight ‘Cupping’ Trend,” Reuters, August 8, 2016, www.reuters.com/article/us-olympics-rio-swimming-phelps-cupping-idUSKCN10J214.
38
Joshua Wolf Shenk, Lincoln’s Melancholy, 58–59.
39
Joshua Wolf Shenk, “Lincoln’s Great Depression,” Atlantic, October 2005.
40
Mayo Clinic Staff, “Electroconvulsive Therapy (ECT),” Mayo Clinic, October 12, 2018, www.mayoclinic.org/tests-procedures/electroconvulsive-therapy/about/pac-20393894.
41
Запрещен к продаже на территории РФ.
42
Brendan L. Smith, “Inappropriate Prescribing,” Monitor on Psychology 43, no. 6 (June 2012): 36, www.apa.org/monitor/2012/06/prescribing.aspx.
43
Daniel G. Amen et al., “Predicting Positive and Negative Treatment Responses to Stimulants with Brain SPECT Imaging.”
44
Daniel G. Amen et al., “Deficits in Regional Cerebral Blood Flow on Brain SPECT Predict Treatment Resistant Depression,” Journal of Alzheimer’s Disease 63, no. 2 (2018): 529-38.
45
Lisa M. Schwartz and Steven Woloshin, “Medical Marketing in the United States, 1997–2016,” Journal of American Medical Association 321, no. 1 (January 1/8, 2019): 80–96.
46
“Review Article Takes Rare Look at Impact of Advertising Psychiatric Drugs”, Brown University press release, September 13, 2016, https://www.brown.edu/news/2016-09-13/advertising.
47
Benedict Carey and Robert Gebeloff, “Many People Taking Antidepressants Discover They Cannot Quit,” New York Times, April 7, 2018, www.nytimes.com/2018/04/07/health /antidepressants-withdrawal-prozac-cymbalta.html.
48
G. M. Goodwin et al., “Emotional Blunting with Antidepressant Treatments: A Survey among Depressed Patients,” Journal of Affective Disorders 221 (October 15, 2017): 31–35.
49
Thomas Insel, “Transforming Diagnosis,” National Institute of Mental Health, April 29, 2013, https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/transforming-diagnosis.shtml.
50
“Mental Illness,” National Institute of Mental Health, February 2019, https://www.nimh.nih.gov/health/statistics/mental-illness.shtml.
51
Ramin Mojtabai and M. Olfson, “Proportion of Antidepressants Prescribed without a Psychiatric Diagnosis Is Growing,” Health Affairs 30, no. 8 (August 2011): 1434-42.
52
Racheli Magnezi et al., “Comparison between Neurostimulation Techniques Repetitive Transcranial Magnetic Stimulation vs Electroconvulsive Therapy for the Treatment of Resistant Depression: Patient Preference and Cost-Effectiveness,” Patient Preference and Adherence 10 (August 4, 2016): 1481-87.
53
Tarique Perera et al., “The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder,” Brain Stimulation 9, no. 3 (May – June 2016): 336-46.
54
D. White and S. Tavakoli, “Repetitive Transcranial Magnetic Stimulation for Treatment of Major Depressive Disorder with Comorbid Generalized Anxiety Disorder,” Annals of Clinical Psychiatry 27, no. 3 (August 2015): 192-96.
55
Marco Ceccanti et al., “Deep TMS on Alcoholics: Effects on Cortisolemia and Dophamine Pathway Modulation. A Pilot Study,” Canadian Journal of Physiology and Pharmacology 93, no. 4 (April 2015): 283-90.
56
Limor Dinur-Klein et al., “Smoking Cessation Induced by Deep Repetitive Transcranial Magnetic Stimulation of the Prefrontal and Insular Cortices: A Prospective, Randomized Controlled Trial,” Biological Psychiatry 76, no. 9 (November 2014): 742-49.
57
Paulo Sergio Boggio et al., “Noninvasive Brain Stimulation with High-Frequency and Low-Intensity Repetitive Transcranial Magnetic Stimulation Treatment for Posttraumatic Stress Disorder,” Journal of Clinical Psychiatry 71, no. 8 (August 2010): 992-99.
58
Alisson Trevizol et al., “Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: An Updated Systematic Review and Meta-Analysis,” Journal of ECT 32, no. 4 (December 2016): 262-66.
59
Hellen Livia Drumond Marra et al., “Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study,” Behavioural Neurology (2015). William M. McDonald, “Neuromodulation Treatments for Geriatric Mood and Cognitive Disorders,” American Journal of Geriatric Psychiatry 24, no. 12 (December 2016): 1130-41. Jose M. Rabey et al., “Repetitive Transcranial Magnetic Stimulation (rTMS) Combined with Cognitive Training Is a Safe and Effective Modality for the Treatment of Alzheimer’s Disease: A Randomized, Double-Blind Study,” Journal of Neural Transmission 123, no. 12 (December 2016): 1449-55.
60
Mehmet Yilmaz et al., “Effectiveness of Transcranial Magnetic Stimulation Application in Treatment of Tinnitus,” Journal of Craniofacial Surgery 25, no. 4 (July 2014): 1315-18.
61
Daniel G. Amen et al., “Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia,” Journal of Alzheimer’s Disease 56, no. 1 (2017): 261–73.
62
Daniel G. Amen et al., “Patterns of Regional Cerebral Blood Flow as a Function of Age throughout the Lifespan,” Journal of Alzheimer’s Disease 65, no. 4 (2018): 1087-92.
63
Chittaranjan Andrade, “Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action,” Journal of Clinical Psychiatry 78, no. 4 (April 2017): e415–e419. Michael F. Grunebaum et al., “Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial,” American Journal of Psychiatry 175, no. 4 (April 1, 2018): 327-35.
64
Nolan R. Williams et al., “Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism,” American Journal of Psychiatry 175, no. 12 (December 1, 2018): 1205-15.
65
Nedra Pickler, “Obama Calls for End to Mental Illness Stigma,” San Diego Union-Tribune, June 3, 2013, www.sandiegouniontribune.com/sdut-obama-calls-for-end-to-mental – illness-stigma-2013jun03-story.html.
66
Michael B. First et al., “Clinical Applications of Neuroimaging in Psychiatric Disorders,” American Journal of Psychiatry 175, no. 9 (September 1, 2018): 915-16.
67
Max Planck, Scientific Autobiography and Other Papers (New York: Philosophical Library, 1949), 33–34.
68
Подробную информацию обо всех книгах автора можно найти в начале книги.
69
Fred A. Mettler Jr. et al., “Radiologic and Nuclear Medicine Studies in the United States and Worldwide: Frequency, Radiation Dose, and Comparison with Other Radiation Sources – 1950–2007,” Radiology 253, no. 2 (November 2009): 520-31.
70
Michael D. Devous et al., “Single-Photon Emission Computed Tomography in Neurotherapeutics,” NeuroRx 2, no. 2 (April 2005): 237-49.
71
Ronald Jack Jaszczak, “The Early Years of Single Photon Emission Computed Tomography (SPECT): An Anthology of Selected Reminiscences,” Physics in Medicine & Biology 51, no. 13 (July 7, 2006): R99-115.
72
“Brain SPECT,” Cedars-Sinai (2019), www.cedars-sinai.edu/Patients/Programs-and-Services/Imaging-Center/For-Patients/Exams-by-Procedure/Nuclear-Medicine/Brain-SPECT.aspx; Mayo Clinic staff, “SPECT Scan,” Mayo Clinic (December 23, 2016), www.mayoclinic.org/tests-procedures/spect-scan/about/pac-20384925.
73
S. Yassin et al., “Differences in SPECT Perfusion in Children and Adolescents with ADHD,” Archives of Clinical Neuropsychology 29, no. 6 (September 2014): 541-42 Daniel G. Amen and B. D. Carmichael, “High-Resolution Brain SPECT Imaging in Attention Deficit Hyperactivity Disorder,” Annals of Clinical Psychiatry 9, no. 2 (June 1997): 81–86.
74
Daniel G. Amen et al., “Predicting Positive and Negative Treatment Responses to Stimulants with Brain SPECT Imaging,” Journal of Psychoactive Drugs 40, no. 2 (June 2008): 131-38.
75
Daniel G. Amen et al., “Patterns of Regional Cerebral Blood Flow as a Function of Age throughout the Lifespan,” Journal of Alzheimer’s Disease 65, no. 4 (September 25, 2018): 1087-92.
76
J. Link et al., “SPECT Differences between Those with Higher and Lower Levels of Aggression: An Exploratory Analysis,” Archives of Clinical Neuropsychology 29, no. 6 (September 2014): 576.
77
Daniel G. Amen et al., “An Analysis of Regional Cerebral Blood Flow in Impulsive Murderers Using Single Photon Emission Computed Tomography,” Journal of Neuropsychiatry and Clinical Neuroscience 19, no. 3 (Summer 2007): 304-9.
78
Jada J. Stewart et al., “Diagnostic Accuracy of SPECT Scans: Examining Specific Brain Areas of Regional Hypoperfusion at Baseline in Alzheimer’s Disease,” Archives of Clinical Neuropsychology (2014).
79
J. Messerly et al., “Preliminary Investigation of SPECT Differences between Individuals with Varying Levels of Anxiety,” Archives of Clinical Neuropsychology 29, no. 6 (September 2014): 579.
80
Daniel G. Amen et al., “Functional Neuroimaging Distinguishes Autistic Spectrum Disorder from Healthy and Comorbid Conditions in Focused and Large Community Datasets,” Journal of Systems and Integrative Neuroscience 3 (April 2017).
81
Daniel G. Amen et al., “Deficits in Regional Cerebral Blood Flow on Brain SPECT Predict Treatment Resistant Depression,” Journal of Alzheimer’s Disease 63, no. 2 (2018): 529-38.
82
Lucas Driskell et al., “A SPECT Exploratory Analysis of Differentiating Mania Symptomology Severity,” Archives of Clinical Neuropsychology 29, no. 6 (September 2014): 578.
83
Daniel G. Amen et al., “Classification of Depression, Cognitive Disorders, and Co-Morbid Depression and Cognitive Disorders with Perfusion SPECT Neuroimaging,” Journal of Alzheimer’s Disease 57, no. 1 (2017): 253-66.
84
Daniel G. Amen et al., “Gender-Based Cerebral Perfusion Differences in 46,034 Functional Neuroimaging Scans,” Journal of Alzheimer’s Disease 60, no. 2 (2017): 605-14.
85
Daniel G. Amen et al., “Functional Neuroimaging Distinguishes Posttraumatic Stress Disorder from Traumatic Brain Injury in Focused and Large Community Datasets,” PLOS One (July 1, 2015), http://journals.plos.org/plosone/article?id=10.1371/journal. pone.0129659. Cyrus A. Raji et al., “Functional Neuroimaging with Default Mode Network Regions Distinguishes PTSD from TBI in a Military Veteran Population,” Brain Imaging and Behavior 9, no. 3 (September 2015): 527-34.
86
Daniel G. Amen et al., “Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia,” Journal of Alzheimer’s Disease 56, no. 1 (2017): 261-73.
87
Andrew B. Newberg et al., “Cerebral Blood Flow Differences between Long-Term Meditators and Non-Meditators,” Consciousness and Cognition 19, no. 4 (December 2010): 899–905. Dharma Khalsa et al., “Cerebral Blood Flow Changes during Chanting Meditation,” Nuclear Medicine Communications 30, no. 12 (December 2009): 956-61.
88
Daniel G. Amen et al., “Quantitative Erythrocyte Omega-3 EPA Plus DHA Levels Are Related to Higher Regional Cerebral Blood Flow on Brain SPECT,” Journal of Alzheimer’s Disease 58, no. 4 (2017): 1189-99.
89
K. Willeumier et al., “Elevated Body Mass in National Football League Players Linked to Cognitive Impairment and Decreased Prefrontal Cortex and Temporal Pole Activity,” Translational Psychiatry 2, no. 1 (January 2012): e68. K. Willeumier et al., “Elevated BMI Is Associated with Decreased Blood Flow in the Prefrontal Cortex Using SPECT Imaging in Healthy Adults,” Obesity 19, no. 5 (May 2011): 1095-97.
90
K. Willeumier et al., “Decreased Cerebral Blood Flow in the Limbic and Prefrontal Cortex Using SPECT Imaging in a Cohort of Completed Suicides,” Translational Psychiatry 1, no. 8 (August 9, 2011): e28. Daniel G. Amen et al., “A Comparative Analysis of Completed Suicide Using High Resolution Brain SPECT Imaging,” Journal of Neuropsychiatry and Clinical Neurosciences 21, no. 4 (Fall 2009): 430-39.
91
Cyrus A. Raji et al., “Clinical Utility of SPECT Neuroimaging in the Diagnosis and Treatment of Traumatic Brain Injury: A Systematic Review,” PLOS One 9, no. 3 (March 19, 2014): e91088.
92
Daniel G. Amen et al., “Perfusion Neuroimaging Abnormalities Alone Distinguish National Football League Players from a Healthy Population,” Journal of Alzheimer’s Disease 53, no. 1 (April 25, 2016): 237-41. Daniel G. Amen et al., “Impact of Playing American Professional Football on Long-Term Brain Function,” Journal of Neuropsychiatry and Clinical Neurosciences 23, no. 1 (Winter 2011): 98-106.
93
Daniel G. Amen et al., “Reversing Brain Damage in Former NFL Players: Implications for Traumatic Brain Injury and Substance Abuse Rehabilitation,” Journal of Psychoactive Drugs 43, no. 1 (January – March 2011): 1–5.
94
Paul G. Harch et al., “A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress Disorder,” Journal of Neurotrauma 29, no. 1 (January 1, 2012): 168-85.
95
Нейрофидбэк – (англ. neurofeedback; также нейротерапия) технология анализа и тренинга функциональной активности головного мозга на основе энцефалографических данных в режиме реального времени. Позволяет человеку контролировать и оптимизировать активность головного мозга.
96
Daniel G. Amen et al., “Predicting Positive and Negative Treatment Responses to Stimulants with Brain SPECT Imaging.”
97
Daniel G. Amen and Blake Carmichael, “Oppositional Children Similar to OCD on SPECT: Implications for Treatment,” Journal of Neurotherapy 2, no. 2 (August 1997): 1–6.
98
Десенсибилизация и переработка движениями глаз (ДПДГ) – форма психотерапии, при которой пациента просят вспомнить тревожные образы; а затем терапевт направляет его в одном из видов двусторонней стимуляции, например в виде движения глаз из стороны в сторону или постукивания по обеим сторонам тела.
99
Подробнее эти принципы рассматриваются в книге Д. Амена «Измените свой мозг – изменится и жизнь!» – Эксмо, 2009.
100
Jonathan Day et al., “Influence of Paternal Preconception Exposures on Their Offspring: Through Epigenetics to Phenotype,” American Journal of Stem Cells 5, no. 1 (2016): 11–18.
101
Erika L. Sabbath et al., “Time May Not Fully Attenuate Solvent-Associated Cognitive Deficits in Highly Exposed Workers,” Neurology 82, no. 19 (May 13, 2014): 1716-23. Samuel Keer et al., “Neuropsychological Performance in Solvent-Exposed Vehicle Collision Repair Workers in New Zealand,” PLOSOne 12, no. 12 (December 13, 2017): e0189108.
102
Амен Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
103
J. Araújo et al., “Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009–2016,” Metabolic Syndrome and Related Disorders 17, no. 1 (February 2019): 46–52.
104
Там же.
105
Michele Corriston, “Demi Lovato Fights for Mental Health Reform on Capitol Hill: ‘I Went through Several Years of Pain and Suffering,’” People, October 5, 2015, people.com/celebrity/demi-lovato-fights-for-mental-health-awareness-in-washington-dc/.
106
Амен Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
107
Eckhart Tolle, “Living in Presence with Your Emotional Pain Body,” HuffPost The Blog, October 6, 2010, www.huffingtonpost.com/eckhart-tolle/living-in-presence-with-y_b_753114.html.
108
Там же.
109
Там же.
110
Jean Twenge, “What Might Explain the Current Unhappiness Epidemic?” Ladders.com, (December 7, 2018), www.theladders.com/career-advice/what-might-explain-the-current-unhappiness-epidemic.
111
M. E. Seligman et al., “Positive Psychology Progress: Empirical Validation of Interventions,” American Psychologist 60, no. 5 (July – August 2005): 410-21.
112
Thomas H. Holmes and Richard H. Rahe, “The Social Readjustment Rating Scale,” Journal of Psychosomatic Research 11, no. 2 (August 1967): 213-18.
113
Emily J. Jones et al., “Chronic Family Stress and Adolescent Health: The Moderating Role of Emotion Regulation,” Psychosomatic Medicine 80, no. 8 (2018): 764-73.
114
Wendy M. Johnston and Graham C. L. Davey, “The Psychological Impact of Negative TV News Bulletins: The Catastrophizing of Personal Worries,” British Journal of Psychology 88, pt. 1 (February 1997): 85–91.
115
Janet Adamy and Paul Overberg, “The Loneliest Generation: Americans, More Than Ever, Are Aging Alone,” Wall Street Journal, December 11, 2018, www.wsj.com/articles/the-loneliest-generation-americans-more-than-ever-are– aging-alone-11544541134.
116
“Loneliness and Alzheimer’s,” Rush University Medical Center, www.rush.edu/healthwellness/discover-health/loneliness-and-alzheimers.
117
Социальные сети, принадлежащие компании Meta, запрещены на территории РФ.
118
Melissa G. Hunt et al., “No More FOMO: Limiting Social Media Decreases Loneliness and Depression,” Journal of Social and Clinical Psychology 37, no. 10 (2018): 751-68. Denis Campbell, “Depression in Girls Linked to Higher Use of Social Media,” Guardian, January 3, 2019, www.theguardian.com/society/2019/jan/04/depression-in-girls-linked-to-higher-use-of-social-media?CMP=Share_iOSApp_Other.
119
Jacqueline V. Hogue and Jennifer S. Mills, “The Effects of Active Social Media Engagement with Peers on Body Image in Young Women,” Body Image 28 (March 2019): 1–5.
120
Lisa Lee, “NIH Study Probes Impact of Heavy Screen Time on Young Brains,” Bloomberg Quint, December 9, 2018, www.bloombergquint.com/technology/screen-time-changes-structure-of-kids-brains-60-minutes-says#gs.ddq1FHk.
121
Larry Magid, “Dire Warnings about Children Dying because of Apps and Games Are a Form of ‘Juvenoia,’” ConnectSafely.org, August 27, 2018, www.connectsafely.org/dire-warnings-about-children-dying-because-of-apps-and-games-are-a-form-of-juvenoia/.
122
Жизель Бюндхен. Lessons. Мой путь к жизни, которая имеет значение. – ОДРИ, 2020.
123
“Frederick’s Experiment,” Digma.com, https://www.digma.com/digma-images/video-scripts/fredericks_experiment.pdf.
124
Harry T. Chugani et al., “Local Brain Functional Activity Following Early Deprivation: A Study of Postinstitutionalized Romanian Orphans,” NeuroImage 14, no. 6 (December 2001): 1290-301.
125
Patricia A. Boyle et al., “Effect of Purpose in Life on Risk of Incident Alzheimer’s Disease and Mild Cognitive Impairment in Community-Dwelling Older Persons,” Archives of General Psychiatry 67, no. 3 (March 2010): 304-10.
126
Там же.
127
Anthony L. Burrow and Nicolette Rainone, “How Many Likes Did I Get?: Purpose Moderates Links between Positive Social Media Feedback and Self-Esteem,” Journal of Experimental Social Psychology 69 (March 2017): 232-36.
128
Амен, Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
129
Байрон, Кейти. Любить то, что есть. Четыре вопроса, которые изменят вашу жизнь. – Бомбора, 2020.
130
“CVD and Mental Health Disorders: Link Established, More Research Needed,” Cardiology Today, November 2015, www.healio.com/cardiology/vascular-medicine/news /print/cardiology-today/%7Bdfb3be16-c566-43d8-9ee0-fbe553b1c35c%7D/cvd-and-mental-health-disorders-link-established-more-research-needed.
131
Kamen A. Tsvetanov et al., “The Effect of Ageing on fMRI: Correction for the Confounding Effects of Vascular Reactivity Evaluated by Joint fMRI and MEG in 335 Adults,” Human Brain Mapping 36, no. 6 (June 2015): 2248-69.
132
Y. Iturria-Medina et al., “Early Role of Vascular Dysregulation on Late-Onset Alzheimer’s Disease Based on Multifactorial Data-Driven Analysis,” Nature Communications 7 (June 21, 2016): 11934.
133
Sebastian Köhler et al., “Depression, Vascular Factors, and Risk of Dementia in Primary Care: A Retrospective Cohort Study,” Journal of the American Geriatrics Society 63, no. 4 (April 2015): 692–98.
134
Justin B. Ng et al., “Heart Disease as a Risk Factor for Dementia,” Clinical Epidemiology 5 (2013): 135-45.
135
James M. Greenblatt, “The Implications of Low Cholesterol in Depression and Suicide,” Great Plains Laboratory, Inc. (November 16, 2015), www.greatplainslaboratory.com/articles-1/2015/11/13/the-implications-of-low-cholesterol-in-depression-and-suicide.
136
Sebastian Köhler et al., “Depression, Vascular Factors, and Risk of Dementia in Primary Care: A Retrospective Cohort Study.” E. Duron and O. Hanon, “Vascular Risk Factors, Cognitive Decline, and Dementia,” Vascular Health and Risk Management 4, no. 2 (2008): 363-81.
137
Sean P. Kennelly et al., “Blood Pressure and the Risk for Dementia: A Double Edged Sword,” Ageing Research Reviews 8, no. 2 (April 2009): 61–70.
138
Chun-Ming Yang et al., “Increased Risk of Dementia in Patients with Erectile Dysfunction: A Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study,” Medicine 94, no. 24 (June 2015): e990.
139
J. Kulmala et al., “Association between Mid-to Late Life Physical Fitness and Dementia: Evidence from the CAIDE Study,” Journal of Internal Medicine 276, no. 3 (September 2014): 296–307. Kay Deckers et al., “Target Risk Factors for Dementia Prevention: A Systematic Review and Delphi Consensus Study on the Evidence from Observational Studies,” International Journal of Geriatric Psychiatry 30, no. 3 (March 2015): 234-46. Robert P. Friedland et al., “Patients with Alzheimer’s Disease Have Reduced Activities in Midlife Compared with Healthy Control-Group Members,” Proceedings of the National Academy of Sciences of the United States of America 98, no. 6 (March 13, 2001): 3440-45.
140
Kaigang Li et al., “Changes in Moderate-to-Vigorous Physical Activity among Older Adolescents,” Pediatrics 138, no. 4 (October 2016): e20161372.
141
Kristen C. Willeumier et al., “Elevated BMI Is Associated with Decreased Blood Flow in the Prefrontal Cortex Using SPECT Imaging in Healthy Adults,” Obesity 19, no. 5 (May 2011): 1095-97.
142
Merideth A. Addicott et al., “The Effect of Daily Caffeine Use on Cerebral Blood Flow: How Much Caffeine Can We Tolerate?” Human Brain Mapping 30, no. 10 (October 2009): 3102-14.
143
Edward F. Domino et al., “Regional Cerebral Blood Flow and Plasma Nicotine after Smoking Tobacco Cigarettes,” Progress in Neuropsychopharmacology and Biological Psychiatry 28, no. 2 (March 2004): 319-27.
144
Daniel G. Amen et al., “Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia,” Journal of Alzheimer’s Disease 56, no. 1 (2017): 261-73.
145
Giuseppe Faraco et al., “Water Deprivation Induces Neurovascular and Cognitive Dysfunction through Vasopressin-Induced Oxidative Stress,” Journal of Cerebral Blood Flow and Metabolism 34, no. 5 (May 2014): 852-60.
146
“Stopping Smoking Is Good for Your Mental Health,” NHS UK, January 25, 2018, www.nhs.uk/live-well/quit-smoking/stopping-smoking-mental-health-benefits/.
147
Yuan-Hwa Chou et al., “Effects of Video Game Playing on Cerebral Blood Flow in Young Adults: A SPECT Study,” Psychiatry Research 212, no. 1 (April 30, 2013): 65–72.
148
Goh Matsuda and Kazuo Hiraki, “Sustained Decrease in Oxygenated Hemoglobin during Video Games in the Dorsal Prefrontal Cortex: A NIRS Study of Children,” Neuroimage 29, no. 3 (February 1, 2006): 706-11.
149
Jack James, “Critical Review of Dietary Caffeine and Blood Pressure: A Relationship That Should Be Taken More Seriously,” Psychosomatic Medicine 66, no. 1 (January – February 2004): 63–71.
150
Andrew Newberg et al., “Cerebral Blood Flow during Meditative Prayer: Preliminary Findings and Methodological Issues,” Perceptual and Motor Skills 97, no. 2 (October 2003): 625-30.
151
Huseyin Naci et al., “How Does Exercise Treatment Compare with Antihypertensive Medications? A Network Meta-Analysis of 391 Randomised Controlled Trials Assessing Exercise and Medication Effects on Systolic Blood Pressure,” British Journal of Sports Medicine 53, no. 14 (July 2019): 859-69.
152
Запрещен на территории РФ.
153
Victoria Allen, “Moderate Exercise Just Three Times a Week and Eating Healthy Can Take 10 Years Off Your Brain Age, Study Says,” Daily Mail (December 19, 2018), www.dailymail.co.uk/news/article-6514359/Moderate-exercise-just-three-times-week-eating-healthy-10-years-brain-age.html.
154
Karmel W. Choi et al., “Assessment of Bidirectional Relationships between Physical Activity and Depression among Adults: A 2-Sample Mendelian Randomization Study,” JAMA Psychiatry 76, no. 4 (April 1, 2019): 399–408.
155
Viola Oertel-Knöchel et al., “Effects of Aerobic Exercise on Cognitive Performance and Individual Psychopathology in Depressive and Schizophrenia Patients,” European Archives of Psychiatry and Clinical Neuroscience 264, no. 7 (October 2014): 589–604.
156
Claudia Battaglia et al., “Participation in a 9-month Selected Physical Exercise Programme Enhances Psychological Well-Being in a Prison Population,” Criminal Behaviour and Mental Health 25, no. 5 (December 2015): 343-54.
157
Richard A. Rawson et al., “The Impact of Exercise on Depression and Anxiety Symptoms among Abstinent Methamphetamine-Dependent Individuals in a Residential Treatment Setting,” Journal of Substance Abuse Treatment 57 (October 2015): 36–40.
158
P. Abedi et al., “Effect of Pedometer-Based Walking on Depression, Anxiety and Insomnia among Postmenopausal Women,” Climacteric 18, no. 6 (2015): 841-45.
159
Laura Q. Rogers et al., “Effects of a Multicomponent Physical Activity Behavior Change Intervention on Fatigue, Anxiety, and Depressive Symptomatology in Breast Cancer Survivors: Randomized Trial,” Psychooncology 26, no. 11 (November 2017): 1901-6.
160
Lisanne F. ten Brinke et al., “Aerobic Exercise Increases Hippocampal Volume in Older Women with Probable Mild Cognitive Impairment: A 6-Month Randomised Controlled Trial,” British Journal of Sports Medicine 49, no. 4 (February 2015): 248-54. Caterina Rosano et al., “Hippocampal Response to a 24-Month Physical Activity Intervention in Sedentary Older Adults,” American Journal of Geriatric Psychiatry 25, no. 3 (November 15, 2016): 209-17. Maike M. Kleemeyer et al., “Changes in Fitness Are Associated with Changes in Hippocampal Microstructure and Hippocampal Volume among Older Adults,” Neuroimage 131 (May 1, 2016): 155-61. F. G. Pajonk et al., “Hippocampal Plasticity in Response to Exercise in Schizophrenia,” Archives of General Psychiatry 67, no. 2 (February 2010): 133-43.
161
Kim M. Gerecke et al., “Exercise Protects against Chronic Restraint Stress-Induced Oxidative Stress in the Cortex and Hippocampus,” Brain Research 1509 (May 6, 2013): 66–78.
162
Vijay R. Varma et al., “Low-Intensity Daily Walking Activity Is Associated with Hippocampal Volume in Older Adults,” Hippocampus 25, no. 5 (May 2015): 605-15.
163
Francesca Calabrese et al., “Brain-Derived Neurotrophic Factor: A Bridge between Inflammation and Neuroplasticity,” Front Cell Neuroscience 8 (December 22, 2014): 430.
164
Carl W. Cotman and N. C. Berchtold, “Exercise: A Behavioral Intervention to Enhance Brain Health and Plasticity,” Trends in Neurosciences 25, no. 6 (June 2002): 295–301. William D. S. Killgore et al., “Physical Exercise Habits Correlate with Gray Matter Volume of the Hippocampus in Healthy Adult Humans,” Scientific Reports 3 (December 12, 2013): 3457.
165
Cell Press, “Physical Activity May Leave the Brain More Open to Change,” ScienceDaily (December 7, 2015), www.sciencedaily.com/releases/2015/12/151207131508.htm.
166
Ana M. Abrantes et al., “A Pilot Randomized Controlled Trial of Aerobic Exercise as an Adjunct to OCD Treatment,” General Hospital Psychiatry 49 (November 2017): 51–55.
167
Mathew G. Fetzner and G. J. Asmundson, “Aerobic Exercise Reduces Symptoms of Posttraumatic Stress Disorder: A Randomized Controlled Trial,” Cognitive Behaviour Therapy 44, no. 4 (2015): 301-13.
168
R. Ryan Patel, “Weight-Lifting, Exercise, and Mental Health,” Ohio State University, October 20, 2017, https://u.osu.edu/emotionalfitness/2017/10/20/weight-lifting – exercise-and-mental-health/.
169
Chien-Yu Pan et al., “A Racket-Sport Intervention Improves Behavioral and Cognitive Performance in Children with Attention-Deficit/Hyperactivity Disorder,” Research in Developmental Disabilities 57 (October 2016): 1-10.
170
Rahav Boussi-Gross et al., “Hyperbaric Oxygen Therapy Can Improve Post Concussion Syndrome Years after Mild Traumatic Brain Injury-Randomized Prospective Trial,” PLoS One 8, no. 11 (November 15, 2013): e79995.
171
Sigal Tal et al., “Hyperbaric Oxygen May Induce Angiogenesis in Patients Suffering from Prolonged Post-Concussion Syndrome Due to Traumatic Brain Injury,” Restorative Neurology and Neuroscience 33, no. 6 (2015): 943-51.
172
Paul G. Harch et al., “A Phase I Study of Low-Pressure Hyperbaric Oxygen Therapy for Blast-Induced Post-Concussion Syndrome and Post-Traumatic Stress Disorder,” Journal of Neurotrauma 29, no. 1 (January 1, 2012): 168-85.
173
Shao-Yuan Chen et al., “Reversible Changes of Brain Perfusion SPECT for Carbon Monoxide Poisoning-Induced Severe Akinetic Mutism,” Clinical Nuclear Medicine 41, no. 5 (May 2016): e221-27.
174
Shai Efrati et al., “Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients-Randomized, Prospective Trial,” PLoS One 8, no. 1 (2013): e53716.
175
Shai Efrati et al., “Hyperbaric Oxygen Therapy Can Diminish Fibromyalgia Syndrome – Prospective Clinical Trial,” PLoS One 10, no. 5 (May 26, 2015): e0127012.
176
Chien-Yu Huang et al., “Hyperbaric Oxygen Therapy as an Effective Adjunctive Treatment for Chronic Lyme Disease,” Journal of the Chinese Medical Association 77, no. 5 (May 2014): 269-71.
177
I-Han Chiang et al., “Adjunctive Hyperbaric Oxygen Therapy in Severe Burns: Experience in Taiwan Formosa Water Park Dust Explosion Disaster,” Burns 43, no. 4 (June 2017): 852-57.
178
M. Löndahl et al., “Relationship between Ulcer Healing after Hyperbaric Oxygen Therapy and Transcutaneous Oximetry, Toe Blood Pressure and Ankle-Brachial Index in Patients with Diabetes and Chronic Foot Ulcers,” Diabetologia 54, no. 1 (January 2011): 65–68.
179
Anne M. Eskes et al., “Hyperbaric Oxygen Therapy: Solution for Difficult to Heal Acute Wounds? Systematic Review,” World Journal of Surgery 35, no. 3 (March 2011): 535-42. Joshua J. Shaw et al., “Not Just Full of Hot Air: Hyperbaric Oxygen Therapy Increases Survival in Cases of Necrotizing Soft Tissue Infections,” Surgical Infections 15, no. 3 (June 2014): 328-35.
180
Mina Taghizadeh Asl et al., “Brain Perfusion Imaging with Voxel-Based Analysis in Secondary Progressive Multiple Sclerosis Patients with a Moderate to Severe Stage of Disease: A Boon for the Workforce,” BMC Neurology 16 (May 26, 2016): 79.
181
P. S. Dulai et al., “Systematic Review: The Safety and Efficacy of Hyperbaric Oxygen Therapy for Inflammatory Bowel Disease,” Alimentary Pharmacology & Therapeutics 39, no. 11 (June 2014): 1266-75.
182
David N. Teguh et al., “Early Hyperbaric Oxygen Therapy for Reducing Radiotherapy Side Effects: Early Results of a Randomized Trial in Oropharyngeal and Nasopharyngeal Cancer,” International Journal of Radiation Oncology, Biology, Physics 75, no. 3 (November 1, 2009): 711-16. Nico Schellart et al., “Hyperbaric Oxygen Treatment Improved Neurophysiologic Performance in Brain Tumor Patients after Neurosurgery and Radiotherapy: A Preliminary Report,” Cancer 117, no. 15 (August 1, 2011): 3434-44.
183
Daniel A. Rossignol et al., “The Effects of Hyperbaric Oxygen Therapy on Oxidative Stress, Inflammation, and Symptoms in Children with Autism: An Open-Label Pilot Study,” BMC Pediatrics 7, no. 36 (November 16, 2007). Daniel A. Rossignol et al., “Hyperbaric Treatment for Children with Autism: A Multicenter, Randomized, DoubleBlind, Controlled Trial,” BMC Pediatrics 9, no. 21 (March 13, 2009).
184
Arun Mukherjee et al., “Intensive Rehabilitation Combined with HBO2 Therapy in Children with Cerebral Palsy: A Controlled Longitudinal Study,” Undersea & Hyperbaric Medicine 41, no. 2 (March – April 2014): 77–85.
185
Claudio Borghi and Arrigo F. G. Cicero, “Nutraceuticals with a Clinically Detectable Blood Pressure-Lowering Effect: A Review of Available Randomized Clinical Trials and Their Meta-Analyses,” British Journal of Clinical Pharmacology 83, no. 1 (January 2017): 163-71.
186
Ameneh Mashayekh et al., “Effects of Ginkgo biloba on Cerebral Blood Flow Assessed by Quantitative MR Perfusion Imaging: A Pilot Study,” Neuroradiology 53, no. 3 (March 2011): 185-91. J. Kleijnen and P. Knipschild, “Ginkgo biloba for Cerebral Insufficiency,” British Journal of Clinical Pharmacology 34, no. 4 (October 1992): 352-58. F. Eckmann, “Cerebral Insufficiency – Treatment with Ginkgo-biloba Extract. Time of Onset of Effect in a Double-Blind Study with 60 Inpatients,” Fortschritte der Medizin 108, no. 29 (October 10, 1990): 557-60.
187
R. F. Santos et al., “Cognitive Performance, SPECT, and Blood Viscosity in Elderly NonDemented People Using Ginkgo biloba,” Pharmacopsychiatry 36, no. 4 (July 2003): 127-33. Joseph A. Mix and W. David Crews Jr., “A Double-Blind, Placebo-Controlled, Randomized Trial of Ginkgo biloba Extract EGb 761® in a Sample of Cognitively Intact Older Adults: Neuropsychological Findings,” Human Psychopharmacology 17, no. 6 (August 2002): 267-77.
188
Horst Herrschaft et al., “Ginkgo Biloba Extract EGb 761® in Dementia with Neuropsychiatric Features: A Randomised, Placebo-Controlled Trial to Confirm the Efficacy and Safety of a Daily Dose of 240 mg,” Journal of Psychiatric Research 46, no. 6 (June 2012): 716-23.
189
Chun-Xiao Dai et al., “Role of Ginkgo Biloba Extract as an Adjunctive Treatment of Elderly Patients with Depression and on the Expression of Serum S100B,” Medicine 97, no. 39 (September 2018): e12421.
190
Helmut Woelk et al., “Ginkgo Biloba Special Extract EGb 761® in Generalized Anxiety Disorder and Adjustment Disorder with Anxious Mood: A Randomized, Double-Blind, Placebo-Controlled Trial,” Journal of Psychiatric Research 41, no. 6 (September 2007): 472-80.
191
Daniel J. Lamport et al., “The Effect of Flavanol-Rich Cocoa on Cerebral Perfusion in Healthy Older Adults during Conscious Resting State: A Placebo Controlled, Crossover, Acute Trial,” Psychopharmacology 232, no. 17 (September 2015): 3227-34. David T. Field et al., “Consumption of Cocoa Flavanols Results in an Acute Improvement in Visual and Cognitive Functions,” Physiology & Behavior 103, nos. 3–4 (June 2011): 255-60. S. T. Francis et al., “The Effect of Flavanol-Rich Cocoa on the fMRI Response to a Cognitive Task in Healthy Young People,” Journal of Cardiovascular Pharmacology 47, suppl 2:S215-20 (June 2006). Farzaneh A. Sorond et al., “Neurovascular Coupling, Cerebral White Matter Integrity, and Response to Cocoa in Older People,” Neurology 81, no. 10 (September 3, 2013): 904-9.
192
Karin Ried et al., “Effect of Cocoa on Blood Pressure,” Cochrane Database of Systematic Reviews 8 (August 15, 2012): CD008893. Karin Ried et al., “Does Chocolate Reduce Blood Pressure? A Meta-Analysis,” BMC Medicine 8, no. 39 (June 28, 2010).
193
Giovambattista Desideri et al., “Benefits in Cognitive Function, Blood Pressure, and Insulin Resistance through Cocoa Flavanol Consumption in Elderly Subjects with Mild Cognitive Impairment: The Cocoa, Cognition, and Aging (CoCoA) Study,” Hypertension 60, no. 3 (September 2012): 794–801. Daniela Mastroiacovo et al., “Cocoa Flavanol Consumption Improves Cognitive Function, Blood Pressure Control, and Metabolic Profile in Elderly Subjects: The Cocoa, Cognition, and Aging (CoCoA) Study – A Randomized Controlled Trial,” American Journal of Clinical Nutrition 101, no. 3 (March 2015): 538-48.
194
Davide Grassi et al., “Flavanol-Rich Chocolate Acutely Improves Arterial Function and Working Memory Performance Counteracting the Effects of Sleep Deprivation in Healthy Individuals,” Journal of Hypertension 34, no. 7 (July 2016): 1298–1308.
195
Mandy Oaklander, “5 Surprising Ways to Help Your Memory,” Time (June 10, 2015), http://time.com/3915030/boost-memory-exercise/. Philippa A. Jackson et al., “DHA-Rich Oil Modulates the Cerebral Haemodynamic Response to Cognitive Tasks in Healthy Young Adults: A Near IR Spectroscopy Pilot Study,” British Journal of Nutrition 107, no. 8 (April 28, 2012): 1093-98. Tae-Jin Song et al., “Low Levels of Plasma Omega 3-Polyunsaturated Fatty Acids Are Associated with Cerebral Small Vessel Diseases in Acute Ischemic Stroke Patients,” Nutrition Research 35, no. 5 (May 2015): 368-74.
196
A. Veronica Witte et al., “Long-Chain Omega-3 Fatty Acids Improve Brain Function and Structure in Older Adults,” Cerebral Cortex 24, no. 11 (November 2014): 3059-68.
197
E. L. Boespflug et al., “Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment,” Journal of Nutrition, Health & Aging 20, no. 2 (February 2016): 161-69.
198
Nina Hamazaki-Fujita et al., “Polyunsaturated Fatty Acids and Blood Circulation in the Forebrain during a Mental Arithmetic Task,” Brain Research 1397 (June 23, 2011): 38–45.
199
Jennifer Mildenberger et al., “N-3 PUFAs Induce Inflammatory Tolerance by Formation of KEAP1-Containing SQSTM1/p62-Bodies and Activation of NFE2L2,” Autophagy 13, no. 10 (October 3, 2017): 1664-78.
200
Fredrik Jernerén et al., “Brain Atrophy in Cognitively Impaired Elderly: The Importance of Long-Chain ω-3 Fatty Acids and B Vitamin Status in a Randomized Controlled Trial,” American Journal of Clinical Nutrition 102, no. 1 (July 2015): 215-21.
201
Emma L. Wightman et al., “Epigallocatechin Gallate, Cerebral Blood Flow Parameters, Cognitive Performance and Mood in Healthy Humans: A Double-Blind, Placebo-Controlled, Crossover Investigation,” Human Psychopharmacology 27, no. 2 (March 2012): 177-86.
202
Xiaoli Peng et al., “Effect of Green Tea Consumption on Blood Pressure: A Meta-Analysis of 13 Randomized Controlled Trials,” Scientific Reports 4 (September 1, 2014): 6251.
203
Xin-Xin Zheng et al., “Green Tea Intake Lowers Fasting Serum Total and LDL Cholesterol in Adults: A Meta-Analysis of 14 Randomized Controlled Trials,” American Journal of Clinical Nutrition 94, no. 2 (August 2011): 601-10.
204
Xin-Xin Zheng et al., “Effects of Green Tea Catechins with or without Caffeine on Glycemic Control in Adults: A Meta-Analysis of Randomized Controlled Trials,” American Journal of Clinical Nutrition 97, no. 4 (April 2013): 750-62.
205
Qiangye Zhang et al., “Effect of Green Tea on Reward Learning in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Pilot Study,” Nutrition Journal 12, no. 84 (June 18, 2013).
206
Qing-Ping Ma et al., “Meta-Analysis of the Association between Tea Intake and the Risk of Cognitive Disorders,” PLoS One 11, no. 11 (November 8, 2016): e0165861. L. Feng et al., “Tea Consumption Reduces the Incidence of Neurocognitive Disorders: Findings from the Singapore Longitudinal Aging Study,” Journal of Nutrition, Health & Aging 20, no. 10 (2016): 1002-9.
207
David O. Kennedy et al., “Effects of Resveratrol on Cerebral Blood Flow Variables and Cognitive Performance in Humans: A Double-Blind, Placebo-Controlled, Crossover Investigation,” American Journal of Clinical Nutrition 91, no. 6 (June 2010): 1590-97. Rachel H. X. Wong et al., “Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus,” Nutrients 8, no. 7 (July 12, 2016): 425.
208
Daniel G. Amen et al., “Patterns of Regional Cerebral Blood Flow as a Function of Age throughout the Lifespan,” Journal of Alzheimer’s Disease 65, no. 4 (2018): 1087-92.
209
D. J. Hare et al., “Is Early-Life Iron Exposure Critical in Neurodegeneration?” Nature Reviews Neurology 11, no. 9 (September 2015): 536-44.
210
R. McClelland et al., “Accelerated Ageing and Renal Dysfunction Links Lower Socioeconomic Status and Dietary Phosphate Intake,” Aging 8, no. 5 (May 2016): 1135-49.
211
L. E. Hebert et al., “Change in Risk of Alzheimer Disease Over Time,” Neurology 75, no. 9 (August 31, 2010): 786-91.
212
“Mental Health of Older Adults,” World Health Organization, December 12, 2017, www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults.
213
W. Cai et al., “Oral Glycotoxins Are a Modifiable Cause of Dementia and the Metabolic Syndrome in Mice and Humans,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 13 (April 1, 2014): 4940-45.
214
“National Poll on Healthy Aging,” University of Michigan (March 2019), ihpi.umich.edu/sites/default/files/2019-03/NPHA_Loneliness-Report_FINAL-022619.pdf.
215
Gabriel H. Sahlgren, “Work Longer, Live Healthier,” IEA discussion paper no. 46 (May 2013), http://iea.org.uk/sites/default/files/publications/files/Work%20Longer,%20Live_Healthier.pdf.
216
Kapil Sayal et al., “Relative Age within the School Year and Diagnosis of Attention-Deficit Hyperactivity Disorder: A Nationwide Population-Based Study,” Lancet Psychiatry 4, no. 11 (November 1, 2017): 868-75.
217
Corey L. M. Keyes, “Authentic Purpose: The Spiritual Infrastructure of Life,” Journal of Management, Spirituality & Religion 8, no. 4 (November 2011): 281-97.
218
P. A. Boyle, et al., “Effect of Purpose in Life on Risk of Incident Alzheimer Disease and Mild Cognitive Impairment in Community-Dwelling Older Persons,” Archives of General Psychiatry 67, no. 3 (March 2010): 304-10.
219
T. J. Holwerda et al., “Feelings of Loneliness, but Not Social Isolation, Predict Dementia Onset: Results from the Amsterdam Study of the Elderly (AMSTEL),” Journal of Neurology, Neurosurgery, and Psychiatry 85, no. 2 (February 2014): 135-42.
220
“Loneliness on the RISE: One in Eight People Have No Close Friends to Turn To,” Express, March 1, 2017, http://www.express.co.uk/news/uk/773002/One-in-eight-people-faced-with-loneliness.
221
Kira Asatryan, “4 Disorders That May Thrive on Loneliness,” Psychology Today, July 23, 2015, https://www.psychologytoday.com/us/blog/the-art-closeness/201507/4-disorders-may-thrive-loneliness.
222
E. E. Lee et al., “High Prevalence and Adverse Health Effects of Loneliness in Community-Dwelling Adults across the Lifespan: Role of Wisdom as a Protective Factor,” International Psychogeriatrics (published online December 18, 2018): 1-16.
223
S. Korkmaz et al., “Frequency of Anemia in Chronic Psychiatry Patients,” Neuropsychiatric Disease and Treatment 11 (October 22, 2015): 2737-41.
224
Joseph Mercola, “Iron: This Life-Saving Mineral Found to Actually Increase Senility in Many,” Mercola, July 19, 2012, http://articles.mercola.com/sites/articles/archive/2012/07/19/excess-iron-leads-to-alzheimers.aspx#_edn1. D. J. Hare et al., “Is Early-Life Iron Exposure Critical in Neurodegeneration?” A. C. Leskovjan et al., “Increased Brain Iron Coincides with Early Plaque Formation in a Mouse Model of Alzheimer’s Disease,” Neuroimage 55, no. 1 (March 1, 2011): 32–38.
225
C. C. Meltzer et al., “Serotonin in Aging, Late-Life Depression, and Alzheimer’s Disease: The Emerging Role of Functional Imaging,” Neuropsychopharmacology 18, no. 6 (June 1998): 407-30.
226
S. E. Hemby et al., “Neuron-Specific Age-Related Decreases in Dopamine Receptor Subtype mRNAs,” Journal of Comparative Neurology 456, no. 2 (February 3, 2003): 176-83. Jean-Claude Dreher et al., “Age-Related Changes in Midbrain Dopaminergic Regulation of the Human Reward System,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 39 (September 30, 2008): 15,106-11.
227
Thomas McNeill and Michael Jakowec, “Neurotransmitters: GABA and Glutamate,” Medicine Encyclopedia (2019), http://medicine.jrank.org/pages/1225/Neurotransmitters-GABA-glutamate.html.
228
J. L. Muir, “Acetylcholine, Aging, and Alzheimer’s Disease,” Pharmacology, Biochemistry, and Behavior 56, no. 4 (April 1997): 687-96.
229
John Hiscock, “Judi Dench Interview: ‘Retirement Is a Rude Word,’” Telegraph, February 21, 2015, https://www.telegraph.co.uk/culture/film/film-news/11420407/Judi-Dench-interview-second-exotic-marigold-hotel.html.
230
S. Samman et al., “Green Tea or Rosemary Extract Added to Foods Reduces Nonheme-Iron Absorption,” American Journal of Clinical Nutrition 73, no. 3 (March 2001): 607-12.
231
Y. Jiao et al., “Iron Chelation in the Biological Activity of Curcumin,” Free Radical Biology and Medicine 40, no. 7 (April 1, 2006): 1152-60.
232
Sonja Hilbrand et al., “Caregiving within and beyond the Family Is Associated with Lower Mortality for the Caregiver: A Prospective Study,” Evolution and Human Behavior 38, no. 3 (May 2017): 397–403.
233
M. C. Carlson et al., “Impact of the Baltimore Experience Corps Trial on Cortical and Hippocampal Volumes,” Alzheimer’s and Dementia 11, no. 11 (November 2015): 1340-48.
234
O. Dean et al., “N-acetylcysteine in Psychiatry: Current Therapeutic Evidence and Potential Mechanisms of Action,” Journal of Psychiatry and Neuroscience 36, no. 2 (March 2011): 78–86.
235
Там же.
236
J. C. Adair et al., “Controlled Trial of N-acetylcysteine for Patients with Probable Alzheimer’s Disease,” Neurology 57, no. 8 (October 23, 2001): 1515-17. W. R. Shankle et al., “CerefolinNAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer’s Disease and Cerebrovascular Disease,” Journal of Alzheimer’s Disease 54, no. 3 (October 4, 2016): 1073-84.
237
Wei Zheng et al., “Huperzine A for Treatment of Cognitive Impairment in Major Depressive Disorder: A Systematic Review of Randomized Controlled Trials,” Shanghai Archives of Psychiatry 28, no. 2 (April 25, 2016): 64–71.
238
Wei Zheng et al., “Adjunctive Huperzine A for Cognitive Deficits in Schizophrenia: A Systematic Review and Meta-Analysis,” Human Psychopharmacology 31, no. 4 (July 2016): 286-95.
239
B. S. Wang et al., “Efficacy and Safety of Natural Acetylcholinesterase Inhibitor Huperzine A in the Treatment of Alzheimer’s Disease: An Updated Meta-Analysis,” Journal of Neural Transmission 116, no. 4 (April 2009): 457-65.
240
M. A. Papandreou et al., “Inhibitory Activity on Amyloid-Beta Aggregation and Antioxidant Properties of Crocus sativus Stigmas Extract and Its Crocin Constituents,” Journal of Agricultural and Food Chemistry 54, no. 23 (November 15, 2006): 8762-68.
241
Shinji Soeda et al., “Neuroprotective Activities of Saffron and Crocin” в The Benefits of Natural Products for Neurogenerative Diseases: Advances in Neurobiology, vol. 12, eds. M. Mohamed Essa, Akbar Mohammed, and Gilles Guillemin (New York: Springer, 2016), 275-92.
242
M. Tsolaki et al., “Efficacy and Safety of Crocus sativus L. in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial,” Journal of Alzheimer’s Disease 54, no. 1 (July 2016): 129-33. S. Akhondzadeh et al., “A 22-Week, Multicenter, Randomized, Double-Blind Controlled Trial of Crocus sativus in the Treatment of Mild-to-Moderate Alzheimer’s Disease,” Psychopharmacology 207, no. 4 (January 2010): 637-43. S. Akhondzadeh et al., “Saffron in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease: A 16-Week, Randomized and Placebo-Controlled Trial,” Journal of Clinical Pharmacy and Therapeutics 35, no. 5 (October 2010): 581-88. M. Farokhnia et al., “Comparing the Efficacy and Safety of Crocus sativus L. with Memantine in Patients with Moderate to Severe Alzheimer’s Disease: A Double-Blind Randomized Clinical Trial,” Human Psychopharmacology 29, no. 4 (July 2014): 351-59.
243
E. Tamaddonfard et al., “Crocin Improved Learning and Memory Impairments in Streptozotocin-Induced Diabetic Rats,” Iranian Journal of Basic Medical Sciences 16, no. 1 (January 2013): 91-100.
244
G. D. Geromichalos et al., “Saffron as a Source of Novel Acetylcholinesterase Inhibitors: Molecular Docking and In Vitro Enzymatic Studies,” Journal of Agricultural and Food Chemistry 60, no. 24 (June 2012): 6131-38.
245
Sabrina Morelli et al., “Neuronal Membrane Bioreactor as a Tool for Testing Crocin Neuroprotective Effect in Alzheimer’s Disease,” Chemical Engineering Journal 305 (December 2016): 69–78. M. Rashedinia et al., “Protective Effect of Crocin on Crolein-Induced Tau Phosphorylation in the Rat Brain,” Acta Neurobiologiae Experimentalis 75, no. 2 (2015): 208-19.
246
N. T. Tildesley et al., “Salvia lavandulaefolia (Spanish Sage) Enhances Memory in Healthy Young Volunteers,” Pharmacology Biochemistry and Behavior 75, no. 3 (June 2003): 669-74. A. B. Scholey et al., “An Extract of Salvia (Sage) with Anticholinesterase Properties Improves Memory and Attention in Healthy Older Volunteers,” Psychopharmacology 198, no. 1 (May 2008): 127-39. D. O. Kennedy et al., “Monoterpenoid Extract of Sage (Salvia lavandulaefolia) with Cholinesterase Inhibiting Properties Improves Cognitive Performance and Mood in Healthy Adults,” Journal of Psychopharmacology 25, no. 8 (August 2011): 1088-100.
247
Mohsen Hamidpour et al., “Chemistry, Pharmacology, and Medicinal Property of Sage (Salvia) to Prevent and Cure Illnesses Such as Obesity, Diabetes, Depression, Dementia, Lupus, Autism, Heart Disease, and Cancer,” Journal of Traditional and Complementary Medicine 4, no. 2 (2014): 82–88.
248
J. Hellhammer et al., “Effects of Soy Lecithin Phosphatidic Acid and Phosphatidylserine Complex (PAS) on the Endocrine and Psychological Responses to Mental Stress,” Stress 7, no. 2 (June 2004): 119-26.
249
S. Hirayama et al., “The Effect of Phosphatidylserine Administration on Memory and Symptoms of Attention-Deficit Hyperactivity Disorder: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial,” Journal of Human Nutrition and Dietetics (April 2014): 27 Suppl 2: 284-91. I. Manor et al., “The Effect of Phosphatidylserine Containing Omega-3 Fatty-Acids on Attention-Deficit Hyperactivity Disorder Symptoms in Children: A Double-Blind Placebo-Controlled Trial, Followed by an Open-Label Extension,” European Psychiatry 27, no. 5 (July 2012): 335-42.
250
Marcus Herdener et al., “Musical Training Induces Functional Plasticity in Human Hippocampus,” Journal of Neuroscience 30, no. 4 (January 2010): 1377-84. B. R. Zendel et al., “Neuroplastic Effects of Music Lessons on Hippocampal Volume in Children with Congenital Hypothyroidism,” Neuroreport 24, no. 17 (December 4, 2013): 947-50. M. S. Oechslin et al., “Hippocampal Volume Predicts Fluid Intelligence in Musically Trained People,” Hippocampus 23, no. 7 (July 2013): 552-58.
251
G. Fond, “Inflammation in Psychiatric Disorders,” European Psychiatry 29, no. 8 (November 2014): 551-52. A. H. Miller et al., “Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation,” Neuropsychopharmacology 42, no. 1 (January 2017): 334-59.
252
J. C. Felger et al., “Inflammation Is Associated with Decreased Functional Connectivity within Corticostriatal Reward Circuitry in Depression,” Molecular Psychiatry 21, no. 10 (October 2016): 1358-65.
253
L. Brundin et al., “Role of Inflammation in Suicide: From Mechanisms to Treatment,” Neuropsychopharmacology 42, no. 1 (January 2017): 271-83.
254
George M. Slavich et al., “Neural Sensitivity to Social Rejection Is Associated with Inflammatory Responses to Social Stress,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 33 (August 17, 2010): 14817-22.
255
C. L. Raison et al., “A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers,” JAMA Psychiatry 70, no. 1 (January 2013): 31–41.
256
O. Köhler et al., “Inflammation and Depression: Combined Use of Selective Serotonin Reuptake Inhibitors and NSAIDs or Paracetamol and Psychiatric Outcomes,” Brain and Behavior 5, no. 8 (August 2015): e00338, doi: 10.1002/brb3.338. R. L. Iyengar et al., “NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis,” American Journal of Medicine 126, no. 11 (November 2013): 1017. e11-8.
257
P. H. Wirtz and R. von Känel, “Psychological Stress, Inflammation, and Coronary Heart Disease,” Current Cardiology Reports 19, no. 11 (September 2017): 111.
258
Megan Clapp et al., “Gut Microbiota’s Effect on Mental Health: The Gut-Brain Axis,” Clinical Practice 7, no. 4 (September 15, 2017): 987.
259
Jennifer Lea Reynolds, “Is There a Connection between Gut Health and ADHD?” U.S. News & World Report, September 8, 2017, https://health.usnews.com/health-care/patient-advice/articles/2017-09-08/is-there-a-connection-between-gut-health-and-adhd.
260
C. Jiang et al., “The Gut Microbiota and Alzheimer’s Disease,” Journal of Alzheimer’s Disease 58, no. 1 (2017): 1-15, doi: 10.3233/JAD-161141. C. A. Köhler et al., “The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease,” Current Pharmaceutical Design 22, no. 40 (2016): 6152-66.
261
Qinghui Mu et al., “Leaky Gut as a Danger Signal for Autoimmune Diseases,” Frontiers in Immunology 8 (May 23, 2017): 598.
262
Iman Salem et al., “The Gut Microbiome as a Major Regulator of the Gut-Skin Axis,” Frontiers in Microbiology 9 (July 10, 2018): 1459.
263
A. C. Logan and M. Katzman, “Major Depressive Disorder: Probiotics May Be an Adjuvant Therapy,” Medical Hypotheses 64, no. 3 (2005): 533-38.
264
A. Kato-Kataoka et al., “Fermented Milk Containing Lactobacillus casei Strain Shirota Prevents the Onset of Physical Symptoms in Medical Students under Academic Examination Stress,” Beneficial Microbes 7, no. 2 (2016): 153-56.
265
Y. Wang et al., “Effects of Alcohol on Intestinal Epithelial Barrier Permeability and Expression of Tight Junction-Associated Proteins,” Molecular Medicine Reports 9, no. 6 (June 2014): 2352-56.
266
L. Möhle et al., “Ly6C(hi) Monocytes Provide a Link between Antibiotic-Induced Changes in Gut Microbiota and Adult Hippocampal Neurogenesis,” Cell Reports 15, no. 9 (May 31, 2016): 1945-56.
267
T. A. Mori and L. J. Beilin, “Omega-3 Fatty Acids and Inflammation,” Current Atherosclerosis Reports 6, no. 6 (November 2004): 461-67. D. Moertl et al., “Dose-Dependent Effects of Omega-3-Polyunsaturated Fatty Acids on Systolic Left Ventricular Function, Endothelial Function, and Markers of Inflammation in Chronic Heart Failure of Nonischemic Origin: A Double-Blind, Placebo-Controlled, 3-Arm Study,” American Heart Journal 161, no. 5 (May 2011): 915.e1-9, doi: 10.1016/j. ahj.2011.02.011. J. G. Devassy et al., “Omega-3 Polyunsaturated Fatty Acids and Oxylipins in Neuroinflammation and Management of Alzheimer Disease,” Advances in Nutrition 7, no. 5 (September 15, 2016): 905-16.
268
“Smoking, High Blood Pressure and Being Overweight Top Three Preventable Causes of Death in the U.S.,” Harvard School of Public Health, April 27, 2009, www.hsph.harvard.edu/news/press-releases/smoking-high-blood-pressure-overweight-preventable-causes-death-us/.
269
E. Messamore et al., “Polyunsaturated Fatty Acids and Recurrent Mood Disorders: Phenomenology, Mechanisms, and Clinical Application,” Progress in Lipid Research 66 (April 2017): 1-13, doi: 10.1016/j.plipres.2017.01.001. J. Sarris et al., “Omega-3 for Bipolar Disorder: Meta-Analyses of Use in Mania and Bipolar Depression,” Journal of Clinical Psychiatry 73, no. 1 (January 2012): 81–86, doi: 10.4088/JCP.10r06710. R. J. Mocking et al., “Meta-Analysis and Meta-Regression of Omega-3 Polyunsaturated Fatty Acid Supplementation for Major Depressive Disorder,” Translational Psychiatry 6, (March 15, 2016).
270
J. R. Hibbeln and R. V. Gow, “The Potential for Military Diets to Reduce Depression, Suicide, and Impulsive Aggression: A Review of Current Evidence for Omega-3 and Omega-6 Fatty Acids,” Military Medicine 179, supplement 11 (November 2014): 117-28. M Huan et al., “Suicide Attempt and n-3 Fatty Acid Levels in Red Blood Cells: A Case Control Study in China,” Biological Psychiatry 56, no. 7 (October 1, 2004): 490-96. M. E. Sublette et al., “Omega-3 Polyunsaturated Essential Fatty Acid Status as a Predictor of Future Suicide Risk,” American Journal of Psychiatry 163, no. 6 (June 2006): 1100–1102. M. D. Lewis et al., “Suicide Deaths of Active-Duty US Military and Omega-3 Fatty-Acid Status: A Case-Control Comparison,” Journal of Clinical Psychiatry 72, no. 12 (December 2011): 1585-90.
271
C. M. Milte et al., “Increased Erythrocyte Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated with Improved Attention and Behavior in Children with ADHD in a Randomized Controlled Three-Way Crossover Trial,” Journal of Attention Disorders 19, no. 11 (November 2015): 954-64. M. H. Bloch and A. Qawasmi, “Omega-3 Fatty Acid Supplementation for the Treatment of Children with Attention-Deficit/Hyperactivity Disorder Symptomatology: Systematic Review and Meta-Analysis,” Journal of the American Academy of Child and Adolescent Psychiatry 50, no. 10 (October 2011): 991-1000.
272
Y. Zhang et al., “Intakes of Fish and Polyunsaturated Fatty Acids and Mild-to-Severe Cognitive Impairment Risks: A Dose-Response Meta-Analysis of 21 Cohort Studies,” American Journal of Clinical Nutrition 103, no. 2 (February 2016): 330-40. T. A. D’Ascoli et al., “Association between Serum Long-Chain Omega-3 Polyunsaturated Fatty Acids and Cognitive Performance in Elderly Men and Women: The Kuopio Ischaemic Heart Disease Risk Factor Study,” European Journal of Clinical Nutrition 70, no. 8 (August 2016): 970-75.
273
C. Couet et al., “Effect of Dietary Fish Oil on Body Fat Mass and Basal Fat Oxidation in Healthy Adults,” International Journal of Obesity and Related Metabolic Disorders 21, no. 8 (August 1997): 637-43. J. D. Buckley and P. R. Howe, “Anti-Obesity Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids,” Obesity Reviews 10, no. 6 (November 2009): 648-59.
274
C. von Schacky, “The Omega-3 Index as a Risk Factor for Cardiovascular Diseases,” Prostaglandins & Other Lipid Mediators 96, nos. 1–4 (November 2011): 94–98. S. P. Whelton et al., “Meta-Analysis of Observational Studies on Fish Intake and Coronary Heart Disease, American Journal of Cardiology 93, no. 9 (May 1, 2004): 1119-23.
275
Daniel G. Amen et al., “Quantitative Erythrocyte Omega-3 EPA Plus DHA Levels Are Related to Higher Regional Cerebral Blood Flow on Brain SPECT,” Journal of Alzheimer’s Disease 58, no. 4 (2017): 1189-99.
276
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 101.
277
R. J. Mocking et al., “Meta-Analysis and Meta-Regression of Omega-3 Polyunsaturated Fatty Acid Supplementation for Major Depressive Disorder.”
278
L. A. Colangelo et al., “Higher Dietary Intake of Long-Chain Omega-3 Polyunsaturated Fatty Acids Is Inversely Associated with Depressive Symptoms in Women,” Nutrition 25, no. 10 (October 2009): 1011-19.
279
Giuseppe Grosso et al., “Omega-3 Fatty Acids and Depression: Scientific Evidence and Biological Mechanisms,” Oxidative Medicine and Cellular Longevity (March 18, 2014).
280
E. Derbyshire, “Do Omega-3/6 Fatty Acids Have a Therapeutic Role in Children and Young People with ADHD?” Journal of Lipids (2017).
281
G. P. Amminger et al., “Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial,” Archives of General Psychiatry 67, no. 2 (February 2010): 146-54.
282
Мукерджи, Сиддхартха. Ген: очень личная история. – Corpus, 2023.
283
Daniel G. Amen and Tana Amen, The Brain Warrior’s Way (New York: New American Library, 2016), 31.
284
Rosaline J. Neuman et al., “Latent Class Analysis of ADHD and Comorbid Symptoms in a Population Sample of Adolescent Female Twins,” Journal of Child Psychology and Psychiatry 42, no. 7 (October 2001): 933-42. Cori Bargmann, “Overview of Genes and Behavior,” YouTube, November 1, 2013, www.youtube.com/watch?v=4qhrnOP8euI&feature=youtu.be.
285
Joshua Wolf Shenk, Lincoln’s Melancholy (New York: Houghton Mifflin, 2005), 80.
286
Brian G. Dias and Kerry J. Ressler, “Parental Olfactory Experience Influences Behavior and Neural Structure in Subsequent Generations,” Nature Neuroscience 17, no. 1 (2014): 89–96.
287
Katharina Gapp et al., “Early Life Stress in Fathers Improves Behavioural Flexibility in Their Offspring,” Nature Communications 5, no. 5466 (2014).
288
Michael J. Gandal et al., “Shared Molecular Neuropathology across Major Psychiatric Disorders Parallels Polygenic Overlap,” Science 359, no. 6376 (February 9, 2018)): 693-97, doi: 10.1126/science.aad6469. D. B. Hancock et al., “Genome-Wide Association Study across European and African American Ancestries Identifies a SNP in DNMT3B Contributing to Nicotine Dependence,” Molecular Psychiatry 23, no. 9 (September 2018): 1911-19.
289
U. Amstutz et al., “Recommendations for HLA-B*15:02 and HLA-A*31:01 Genetic Testing to Reduce the Risk of Carbamazepine-Induced Hypersensitivity Reactions,” Epilepsia 55, no. 4 (April 2014): 496–506 doi: 10.1111/epi.12564.
290
Joe Namuth, interview by Howard Stern, “How Joe Namath Reversed His Own Brain Damage Caused by Football,” The Howard Stern Show, June 24, 2019, www.youtube.com/watch?v=s7nxU3QadIA&feature=youtu.be.
291
“Traumatic Brain Injury and Concussion,” Centers for Disease Control and Prevention, March 3, 2019, www.cdc.gov/traumaticbraininjury/get_the_facts.html.
292
Blue Cross Blue Shield, “The Health of America Report: The Steep Rise in Concussion Diagnoses in the U.S.,” September 27, 2016, https://www.bcbs.com/the-health-of-america/reports/the-steep-rise-concussion-diagnoses-the-us.
293
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 124-25.
294
Alana Semuels, “The White Flight from Football,” Atlantic, February 1, 2019, www.theatlantic.com/health/archive/2019/02/football-white-flight-racial-divide/581623/.
295
“DoD Worldwide Numbers for TBI,” Defense and Veterans Brain Injury Center, July 7, 2019, http://dvbic.dcoe.mil/dod-worldwide-numbers-tbi.
296
A. L. Zaninotto et al., “Updates and Current Perspectives of Psychiatric Assessments after Traumatic Brain Injury: A Systematic Review,” Frontiers in Psychiatry 7 (June 14, 2016): 95.
297
R. J. Schachar et al., “Mental Health Implications of Traumatic Brain Injury (TBI) in Children and Youth,” Journal of Canadian Academy of Child and Adolescent Psychiatry 24, no. 2, (Fall 2015): 100–108.
298
Daryl and Daniel C. Fujii, “Psychotic Disorder Due to Traumatic Brain Injury: Analysis of Case Studies in the Literature,” Journal of Neuropsychiatry and Clinical Neurosciences 24, no. 3 (Summer 2012): 278-89.
299
G. J. McHugo et al., “The Prevalence of Traumatic Brain Injury among People With Co-Occurring Mental Health and Substance Use Disorders,” Journal of Head Trauma Rehabilitation 32, no. 3 (May/June 2017): E65-E74.
300
Jessica L. Mackelprang et al., “Adverse Outcomes among Homeless Adolescents and Young Adults Who Report a History of Traumatic Brain Injury,” American Journal of Public Health 104, no. 10 (October 2014): 1986-92.
301
Там же.
302
Schachar et al., “Mental Health Implications of Traumatic Brain Injury (TBI).”
303
R. Lajiness-O’Neill et al., “Memory and Learning in Pediatric Traumatic Brain Injury: A Review and Examination of Moderators of Outcome,” Applied Neuropsychology 17, no. 2 (April 2010): 83–92.
304
G. J. McHugo et al., “The Prevalence of Traumatic Brain Injury among People with Co-Occurring Mental Health and Substance Use Disorders,” Journal of Head Trauma Rehabilitation 32, no. 3 (May/June 2017): E65-E74.
305
R. C. Gardner et al., “Dementia Risk after Traumatic Brain Injury vs Nonbrain Trauma: The Role of Age and Severity,” JAMA Neurology 17, no. 12 (December 2014): 1490-97.
306
V. Rao et al., “Aggression after Traumatic Brain Injury: Prevalence and Correlates,” Journal of Neuropsychiatry and Clinical Neurosciences 21, no. 4 (2009): 420-29.
307
J. Topolovec-Vranic et al., “Traumatic Brain Injury among People Who Are Homeless: A Systematic Review,” BMC Public Health 12 (December 2012): 1059.
308
Mackelprang, “Adverse Outcomes among Homeless Adolescents,” 1986-92.20. P. J. Schechter and R. I. Henkin, “Abnormalities of Taste and Smell after Head Trauma,” Journal of Neurology, Neurosurgery, and Psychiatry 35, no. 7 (1974): 802-10.
309
“One in Four Prisoners Have Suffered Traumatic Brain Injury, Study Finds,” Glasgow Live, January 18, 2019, www.glasgowlive.co.uk/news/glasgow-news/ one-four-prisoners-suffered-traumatic-15695721.
310
Brian Im et al., “TBI and Incarceration,” American Psychological Association, December 2014, www.apa.org/pi/disability/resources/publications/newsletter/2014/12/incarceration.
311
Jennifer Bronson et al., “Veterans in Prison and Jail, 2011–2012,” Bureau of Justice Statistics, December 7, 2015, https://www.bjs.gov/index.cfm?ty=pbdetail&iid=5479.
312
задаю эти вопросы всем моим пациентам. Обзор их ответов можно найти в моей книге «Спасение памяти» (Memory Rescue, 134).
313
Daniel F. Mackay et al., “Neurodegenerative Disease Mortality among Former Professional Soccer Players,” New England Journal of Medicine (October 21, 2019), https://doi:10.1056/NEJMoa1908483.
314
“Fighting in Ice Hockey,” Wikipedia, June 12, 2019, en.wikipedia.org/wiki/Fighting_in _ice_hockey.
315
H. Ling et al., “Mixed Pathologies Including Chronic Traumatic Encephalopathy Account for Dementia in Retired Association Football (Soccer) Players,” Acta Neuropathologica 133, no. 3 (March 2017): 337–352.
316
T. Surmeli et al., “Quantitative EEG Neurometric Analysis-Guided Neurofeedback Treatment in Postconcussion Syndrome (PCS): Forty Cases. How Is Neurometric Analysis Important for the Treatment of PCS and as a Biomarker?” Clinical EEG and Neuroscience 48, no. 3 (June 27, 2016): 217-30.
317
E. J. Cheon et al., “The Efficacy of Neurofeedback in Patients with Major Depressive Disorder: An Open Labeled Prospective Study,” Applied Psychophysiology and Biofeedback 41, no. 1 (March 2016): 103-10.
318
V. Meisel et al., “Neurofeedback and Standard Pharmacological Intervention in ADHD: A Randomized Controlled Trial with Six-month Follow-up,” Biological Psychology 94, no. 1 (September 2013): 12–21.
319
J. Kopřivová et al., “Prediction of Treatment Response and the Effect of Independent Component Neurofeedback in Obsessive-Compulsive Disorder: A Randomized, Sham-Controlled, Double-Blind Study,” Neuropsychobiology 67, no. 4 (2013): 210-23.
320
R. Rostami and F. Dehghani-Arani, “Neurofeedback Training as a New Method in Treatment of Crystal Methamphetamine Dependent Patients: A Preliminary Study,” Applied Psychophysiological Biofeedback 40, no. 3 (September 2015): 151-61.
321
J. Guez et al., “Influence of Electroencephalography Neurofeedback Training on Episodic Memory: A Randomized, Sham-Controlled, Double-Blind Study,” Memory 23, no. 5 (2015): 683-94. S. Xiong et al., “Working Memory Training Using EEG Neurofeedback in Normal Young Adults,” Bio-Medical Materials and Engineering 24, no. 6 (2014): 3637-44. J. R. Wang and S. Hsieh, “Neurofeedback Training Improves Attention and Working Memory Performance,” Clinical Neurophysiology 124, no. 12 (December 2013): 2406-20.
322
S. E. Kober et al., “Specific Effects of EEG Based Neurofeedback Training on Memory Functions in Post-Stroke Victims,” Journal of NeuroEngineering and Rehabilitation 12 (December 2015): 107.
323
P. Kubik et al., “Neurofeedback Therapy Influence on Clinical Status and Some EEG Parameters in Children with Localized Epilepsy,” Przegl Lek 73, no. 3 (2016): 157-60.
324
M. P. Jensen et al. “Use of Neurofeedback to Enhance Response to Hypnotic Analgesia in Individuals with Multiple Sclerosis,” International Journal of Clinical and Experimental Hypnosis 64, no 1 (2016): 1-23.
325
A. Azarpaikan et al., “Neurofeedback and Physical Balance in Parkinson’s Patients,” Gait & Posture 40, no. 1 (2014): 177-81.
326
Michael D. Lewis, When Brains Collide: What Every Athlete and Parent Should Know about the Prevention and Treatment of Concussions and Head Injuries (n.p.: Lioncrest Publishing, 2016).
327
Ian H. Stanley et al., “A Systematic Review of Suicidal Thoughts and Behaviors among Police Officers, Firefighters, EMTs, and Paramedics,” Clinical Psychology Review 44 (March 2016): 25–44. Samuel B. Harvey et al., “The Mental Health of Fire-Fighters: An Examination of the Impact of Repeated Trauma Exposure,” Australian and New Zealand Journal of Psychiatry 50, no. 7 (July 2016): 649-58.
328
Melanie A. Hom et al., “Mental Health Service Use among Firefighters with Suicidal Thoughts and Behaviors,” Psychiatric Services 67, no. 6 (June 1, 2016): 688-91
329
Yasser Iturria-Medina et al., “Early Role of Vascular Dysregulation on LateOnset Alzheimer’s Disease Based on Multifactorial Data-Driven Analysis,” Nature Communications 7 (June 21, 2016): 11934.
330
Eric Emerson et al., “Risk of Exposure to Air Pollution among British Children with and without Intellectual Disabilities,” Journal of Intellectual Disability Research 63, no. 2 (February 2019): 161-67.
331
Tesifon Parrón et al., “Association between Environmental Exposure to Pesticides and Neurodegenerative Diseases,” Toxicology and Applied Pharmacology 256, no. 3 (November 1, 2011): 379-85.
332
“Don’t Pucker Up: Lead in Lipstick,” Campaign for Safe Cosmetics, October 12, 2007, http://www.safecosmetics.org/about-us/media/news-coverage/dont-pucker-up-lead – in-lipstick/.
333
См. также Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017).
334
Amen, Memory Rescue, 145-46.
335
Там же, 144-45.
336
Curt T. DellaValle et al., “Dietary Nitrate and Nitrite Intake and Risk of Colorectal Cancer in the Shanghai Women’s Health Study,” International Journal of Cancer 134, no. 12 (June 15, 2014): 2917-26.
337
Kim Harley, “The Health Costs of Beauty: EDCs in Personal Care Products and the HERMOSA Study,” Collaborative on Health and the Environment, March 22, 2016, www. healthandenvironment.org/partnership_calls/18271. Suzanne M. de la Monte et al., “Epidemilogical Trends Strongly Suggest Exposures as Etiologic Agents in the Pathogenesis of Sporadic Alzheimer’s Disease, Diabetes Mellitus, and Non-Alcoholic Steatohepatitis,” Journal of Alzheimer’s Disease 17, no. 3 (2009): 519-29.
338
Céline Gasnier et al., “Glyphosate-Based Herbicides Are Toxic and Endocrine Disruptors in Human Cell Lines,” Toxicology 262, no. 3 (August 21, 2009): 184-91.
339
Luoping Zhang et al., “Exposure to Glyphosate-Based Herbicides and Risk for NonHodgkin Lymphoma: A Meta-analysis and Supporting Evidence,” Mutation Research/ Reviews in Mutation Research 781 (July – September 2019): 186–206.
340
Ki-Su Kim et al., “Associations between Organochlorine Pesticides and Cognition in U.S. Elders: National Health and Nutrition Examination Survey 1999–2002,” Environment International 75 (February 2015): 87–92.
341
Kaarin J. Anstey et al., “Alcohol Consumption as a Risk Factor for Dementia and Cognitive Decline: Meta-analysis of Prospective Studies,” American Journal of Geriatric Psychiatry 17, no. 7 (July 2009): 542-55. Ruth Peters et al., “Alcohol, Dementia and Cognitive Decline in the Elderly: A Systematic Review,” Age and Aging 37, no. 5 (September 2008): 505-12. Edward Neafsey and Michael A. Collins, “Moderate Alcohol Consumption and Cognitive Risk,” Neuropsychiatric Disease and Treatment 7 (2011): 465-84.
342
Jingzhong Ding et al., “Alcohol Intake and Cerebral Abnormalities on Magnetic Resonance Imaging in a Community-Based Population of Middle-Aged Adults: The Atherosclerosis Risk in Communities (ARIC) Study,” Stroke 35, no. 1 (January 2004): 16–21.
343
George F. Koob, “Neurobiology of Addiction: Toward the Development of New Therapies,” Annals of the New York Academy of Sciences 909 (2000): 170-85.
344
Elizabeth P. Handing et al., “Midlife Alcohol Consumption and Risk of Dementia over 43 Years of Follow-Up: A Population-Based Study from the Swedish Twin Registry,” Journals of Gerontology: Series A 70, no. 10 (October 2015): 1248-54.
345
Jennie Connor, “Alcohol Consumption as a Cause of Cancer,” Addiction 112, no. 2 (February 2017): 222-28.
346
Zach Walsh et al., “Medical Cannabis and Mental Health: A Guided Systematic Review,” Clinical Psychology Review 51 (February 2017): 15–29.
347
Daniel G. Amen et al., “Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia,” Journal of Alzheimer’s Disease 56, no. 1 (2017): 261-73.
348
Gobbi et al., “Association of Cannabis Use in Adolescence,” 426-34.
349
Marta Di Forti et al., “The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder across Europe (EU-GEI): A Multicentre Case-Control Study,” Lancet Psychiatry 6, no. 5 (May 2019): 427-36.
350
Judith Prochaska et al., “Tobacco Use among Individuals with Schizophrenia: What Role Has the Tobacco Industry Played?” Schizophrenia Bulletin 34, no. 3 (May 2008): 555-67. Используется с разрешения.
351
Prochaska et al., “Tobacco Use among Individuals with Schizophrenia,” 555-67.
352
“Tobacco Use among Adults with Mental Illness and Substance Use Disorders,” Centers for Disease Control and Prevention, last reviewed January 14, 2019, https://www.cdc.gov/tobacco/disparities/mental-illness-substance-use/index.htm.
353
“Teens Using Vaping Devices in Record Numbers,” National Institute on Drug Abuse, December 17, 2018, https://www.drugabuse.gov/news-events/news-releases/2018/12/teens-using-vaping-devices-in-record-numbers.
354
“Surgeon General’s Advisory on E-cigarette Use among Youth,” Office of the US Surgeon General, 2018, https://e-cigarettes.surgeongeneral.gov/documents/surgeon-generals – advisory-on-e-cigarette-use-among-youth-2018.pdf.
355
Amen, Memory Rescue, 152.
356
Amen, Memory Rescue, 152-53.
357
James S. Brown Jr., “Introduction: An Update on Psychiatric Effects of Toxic Exposures,” Psychiatric Times 33, no. 9 (October 1, 2016).
358
Amanda Habermann, “Lead Poisoning’s Harmful Impact on Physical and Mental Health,” Sovereign Health, February 20, 2016, https://www.sovhealth.com/health-and-wellness /lead-poisonings-harmful-impact-on-physical-and-mental-health/.
359
Brown, “Update on Psychiatric Effects of Toxic Exposures.”
360
Maryse F. Bouchard et al., “Blood Lead Levels and Major Depressive Disorder, Panic Disorder, and Generalized Anxiety Disorder in US Young Adults,” Archives of General Psychiatry 66, no. 12 (December 2009): 1313-19.
361
“Don’t Pucker Up,” Campaign for Safe Cosmetics.
362
Sa Liu, Sally Katharine Hammond, and Ann Rojas-Cheatham, “Concentrations and Potential Health Risks of Metals in Lip Products,” Environmental Health Perspectives 121, no. 6 (June 2013): 705-10.
363
Amen, Memory Rescue, 153.
364
Edward A. Bittner, Yun Yue, and Zhongcong Xie, “Brief Review: Anesthetic Neurotoxicity in the Elderly, Cognitive Dysfunction and Alzheimer’s Disease,” Canadian Journal of Anesthesia 58, no. 2 (February 2011): 216-23. Chia-Wen Chen et al., “Increased Risk of Dementia in People with Previous Exposure to General Anesthesia: A Nationwide Population-Based Case-Control Study,” Alzheimer’s and Dementia 10, no. 2 (March 2014): 196–204.
365
Barynia Backeljauw et al., “Cognition and Brain Structure following Early Childhood Surgery with Anesthesia,” Pediatrics 136, no. 1 (July 2015): e1-12.
366
Ефимова Н.Ю. и др. Изменение мозгового кровотока и когнитивной функции у больных, перенесших операцию коронарного шунтирования в условиях искусственного кровообращения. Кардиология 55, № 6 (Июнь, 2015): 40–46.
367
University of Rochester Medical Center, “Chemotherapy’s Damage to the Brain Detailed,” ScienceDaily, April 22, 2008, https://www.sciencedaily.com/releases/2008/04/080422103947.htm.
368
Harley, “Health Costs of Beauty”.
369
A. Guttmann, “Advertising Spending in the Perfumes, Cosmetics, and Other Toilet Preparations Industry in the United States from 2010 to 2019 (in Million U.S. Dollars),” Statista, last edited November 29, 2018, https://www.statista.com/statistics/470467/perfumes-cosmetics-and-other-toilet-preparations-industry-ad-spend-usa/.
370
Stacy Malkan, “Johnson & Johnson Is Just the Tip of the Toxic Iceberg,” Time, March 2, 2016, https://time.com/4239561/johnson-and-johnson-toxic-ingredients/.
371
Duke University, “Children Carry Evidence of Toxins from Home Flooring and Furniture,” EurekAlert! American Association for the Advancement of Science (Heather M. Stapleton et al., “Children’s Exposure to Chemicals Emitted from the Home Environment,” presented at AAAS annual meeting, February 17, 2019), https://eurekalert.org/pub_releases/2019-02/du-cce021419.php.
372
Joseph Pizzorno, The Toxin Solution: How Hidden Poisons in the Air, Water, Food, and Products We Use Are Destroying Our Health – And What We Can Do to Fix It (New York: HarperOne, 2018).
373
Petra M. Gaum et al., “Prevalence and Incidence Rates of Mental Syndromes after Occupational Exposure to Polychlorinated Biphenyls,” International Journal of Hygiene and Environmental Health 217, no. 7 (May 27, 2014): 765-74.
374
Dongren Yang et al., “Developmental Exposure to Polychlorinated Biphenyls Interferes with Experience-Dependent Dendritic Plasticity and Ryanodine Receptor Expression in Weanling Rats,” Environmental Health Perspectives 117, no. 3 (March 2009): 426-35. Montserrat Samsó et al., “Coordinated Movement of Cytoplasmic and Transmembrane Domains of RyR1 upon Gating,” PLOS Biology 7, no. 4 (April 2009): e1000085.
375
Lynda Ann Frassetto, Ralph Curtis Morris Jr., and Antonio Sebastian, “Effect of Age on Blood Acid-Base Composition in Adult Humans: Role of Age-Related Renal Functional Decline,” American Journal of Physiology – Renal Physiology 271, no. 6 (December 1996): F1114-22.
376
Alena Hall, “What Happened after One Family Went Organic for Just Two Weeks,” HuffPost Life, May 14, 2015, https://www.huffpost.com/entry/the-organic-effect_n _7244000.
377
Cynthia L. Curl, Richard A. Fenske, and Kai Elgethun, “Organophosphorus Pesticide Exposure of Urban and Suburban Preschool Children with Organic and Conventional Diets,” Environmental Health Perspectives 111, no. 3 (March 2003): 377-82.
378
Wahyu Wulaningsih et al., “Investigating Nutrition and Lifestyle Factors as Determinants of Abdominal Obesity: An Environment-Wide Study,” International Journal of Obesity 41, no. 2 (February 2017): 340-47.
379
Sharon P. G. Fowler, “Low-Calorie Sweetener Use and Energy Balance: Results from Experimental Studies in Animals, and Large-Scale Prospective Studies in Humans,” Physiology and Behavior 164, part B (October 1, 2016): 517-23.
380
Moreno Paolini et al., “Aspartame, a Bittersweet Pill,” Carcinogenesis 38, no. 12 (December 2017): 1249-50. Morando Soffritti et al., “The Carcinogenic Effects of Aspartame: The Urgent Need for Regulatory Re-evaluation,” American Journal of Industrial Medicine 57, no. 4 (April 2014): 383-97.73. Jodi E. Nettleton, Raylene A. Reimer, and Jane Shearer, “Reshaping the Gut Microbiota: Impact of Low Calorie Sweeteners and the Link to Insulin Resistance?” Physiology and Behavior 164, part B (October 1, 2016): 488-93. Jotham Suez et al., “Artificial Sweeteners Induce Glucose Intolerance by Altering the Gut Microbiota,” Nature 514, no. 7521 (October 9, 2014): 181–86.
381
Amen, Memory Rescue, 160.
382
Там же, 160-61.
383
Sarah Yang, “Teen Girls See Big Drop in Chemical Exposure with Switch in Cosmetics,” Berkeley News, March 7, 2016, https://news.berkeley.edu/2016/03/07/ cosmetics-chemicals/.
384
Dana Edwin King, Arch G. Mainous, and Carol A. Lambourne, “Trends in Dietary Fiber Intake in the United States, 1999–2008,” Journal of the Academy of Nutrition and Dietetics 112, no. 5 (May 2012): 642-48.
385
Robert J. Flanagan and T. J. Meridith, “Use of N-acetylcysteine in Clinical Toxicology,” American Journal of Medicine 91, no. 3, suppl. 3 (September 30, 1991): S131-39.
386
Reinhold Kirchhoff et al., “Increase in Choleresis by Means of Artichoke Extract,” Phytomedicine 1, no. 2 (September 1994): 107-15.
387
Suzan M. Mansour et al., “Ginkgo Biloba Extract (EGb 761) Normalizes Hypertension in 2K, 1C Hypertensive Rats: Role of Antioxidant Mechanisms, ACE Inhibiting Activity and Improvement of Endothelial Dysfunction,” Phytomedicine 18, nos. 8–9 (June 15, 2011): 641-47.
388
Kültiğin Cavuşoğlu et al., “Protective Effect of Ginkgo Biloba L. Leaf Extract against Glyphosate Toxicity in Swiss Albino Mice,” Journal of Medicinal Food 14, no. 10 (October 2011): 1263-72.
389
Shi-Sheng Zhou et al., “The Skin Function: A Factor of Anti-Metabolic Syndrome,” Diabetology and Metabolic Syndrome 4, no. 1 (April 26, 2012): 15.
390
Margaret E. Sears, Kathleen J. Kerr, and Riina I. Bray, “Arsenic, Cadmium, Lead, and Mercury in Sweat: A Systematic Review,” Journal of Environmental and Public Health 2012 (2012): 184745. Stephen J. Genuis et al., “Blood, Urine, and Sweat (BUS) Study: Monitoring and Elimination of Bioaccumulated Toxic Elements,” Archives of Environmental Contamination and Toxicology 61, no. 2 (August 2011): 344-57.
391
Margaret E. Sears and Stephen J. Genuis, “Environmental Determinants of Chronic Disease and Medical Approaches: Recognition, Avoidance, Supportive Therapy, and Detoxification,” Journal of Environmental and Public Health 2012 (2012): 356798.
392
H. Lew and A. Quintanilha, “Effects of Endurance Training and Exercise on Tissue Antioxidative Capacity and Acetaminophen Detoxification,” European Journal of Drug Metabolism and Pharmacokinetics 16, no. 1 (January – March 1991): 59–68. Chandan K. Sen, “Glutathione Homeostasis in Response to Exercise Training and Nutritional Supplements,” Molecular and Cellular Biochemistry 196, nos. 1–2 (June 1999): 31–42.
393
Margaret O. Murphy et al., “Exercise Protects against PCB-Induced Inflammation and Associated Cardiovascular Risk Factors,” Environmental Science and Pollution Research 23, no. 3 (February 2016): 2201-11.
394
Stephen J. Genuis et al., “Human Elimination of Phthalate Compounds: Blood, Urine, and Sweat (BUS) Study,” Scientific World Journal 2012 (2012): 615068.
395
Stephen J. Genuis et al., “Human Excretion of Bisphenol A: Blood, Urine, and Sweat (BUS) Study,” Journal of Environmental and Public Health 2012 (2012): 185731.
396
Kaye H. Kilburn, Raphael H. Warsaw, and Megan G. Shields, “Neurobehavioral Dysfunction in Firemen Exposed to Polychlorinated Biphenyls (PCBs): Possible Improvement after Detoxification,” Archives of Environmental Health 44, no. 6 (1989): 345-50.
397
Tanjaniina Laukkanen et al., “Sauna Bathing Is Inversely Associated with Dementia and Alzheimer’s Disease in Middle-Aged Finnish Men,” Age and Aging 46, no. 2 (March 1, 2017): 245-49.
398
Tanjaniina Laukkanen et al., “Association between Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events,” JAMA Internal Medicine 175, no. 4 (April 2015): 542-48.
399
Kelli F. Koltyn et al., “Changes in Mood State following Whole-Body Hyperthermia,” International Journal of Hyperthermia 8, no. 3 (May/June 1992): 305-7.
400
K. Kukkonen-Harjula and K. Kauppinen, “How the Sauna Affects the Endocrine System,” Annals of Clinical Research 20, no. 4 (1988): 262-66. D. Jezová et al., “Rise in Plasma Beta-endorphin and ACTH in Response to Hyperthermia in Sauna,” Hormone and Metabolic Research 17, no. 12 (December 1985): 693-94.
401
K. Kukkonen-Harjula et al., “Haemodynamic and Hormonal Responses to Heat Exposure in a Finnish Sauna Bath,” European Journal of Applied Physiology and Occupational Physiology 58, no. 5 (1989): 543-50.
402
Satoshi Kokura et al., “Whole Body Hyperthermia Improves Obesity-Induced Insulin Resistance in Diabetic Mice,” International Journal of Hyperthermia 23, no. 3 (May 2007): 259-65.
403
Laukkanen et al., Association between “Sauna Bathing and Fatal Cardiovascular and All-Cause Mortality Events,” 542-48.
404
Ronald C. Kessler et al., “Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication,” Archives of General Psychiatry 62, no. 6 (June 2005): 617-27.
405
Jack Dreyfus, A Remarkable Medicine Has Been Overlooked (New York: Dreyfus Medical Foundation, 1992).
406
Emil Kraepelin and A. Ross Diefendorf, Clinical Psychiatry (New York: Macmillan, 1907; Delmar, NY: Scholars’ Facsimiles and Reprints, 1981).
407
Luke Plunkett, “The Banned Pokémon Episode That Gave Children Seizures,” Kotaku, October 20, 2015, https://kotaku.com/the-banned-pokemon-episode-that-gave-children-seizures-5757570.
408
Там же.
409
Kirsty Martin et al., “Ketogenic Diet and Other Dietary Treatments for Epilepsy,” Cochrane Database of Systematic Reviews, no. 2 (February 9, 2016): CD001903.
410
Emmanuelle C. Bostock, Kenneth C. Kirby, and Bruce V. Taylor, “The Current Status of the Ketogenic Diet in Psychiatry,” Frontiers in Psychiatry 8 (March 20, 2017): 43. Elisa Brietzke et al., “Ketogenic Diet as a Metabolic Therapy for Mood Disorders: Evidence and Developments,” Neuroscience and Biobehavioral Reviews 94 (November 2018): 11–16. James R. Phelps, Susan V. Siemers, and Rif S. El-Mallakh, “The Ketogenic Diet for Type II Bipolar Disorder,” Neurocase 19, no. 5 (2013): 423-26.
411
Laura R. Saslow et al., “An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations versus a Plate Method Diet in Overweight Individuals with Type 2 Diabetes: A Randomized Controlled Trial,” Journal of Medical Internet Research 19, no. 2 (February 13, 2017): e36.
412
Antonio Paoli et al., “Nutrition and Acne: Therapeutic Potential of Ketogenic Diets,” Skin Pharmacology and Physiology 25, no. 3 (2012): 111-17.
413
Daniela D. Weber, Sepideh Aminzadeh-Gohari, and Barbara Kofler, “Ketogenic Diet in Cancer Therapy,” Aging 10, no. 2 (February 11, 2018): 164-65.
414
Javad Anjom-Shoae et al., “The Association between Dietary Intake of Magnesium and Psychiatric Disorders among Iranian Adults: A Cross-Sectional Study,” British Journal of Nutrition 120, no. 6 (September 2018): 693–702.
415
Alan W. Yuen and Josemir Sander, “Can Magnesium Supplementation Reduce Seizures in People with Epilepsy? A Hypothesis,” Epilepsy Research 100, nos. 1–2 (June 2012): 152-56.
416
Etienne Pouteau et al., “Superiority of Magnesium and Vitamin B6 over Magnesium Alone on Severe Stress in Healthy Adults with Low Magnesemia: A Randomized, SingleBlind Clinical Trial,” PLOS One 13, no. 12 (December 18, 2018): e0208454.
417
Anna E. Kirkland, Gabrielle L. Sarlo, and Kathleen F. Holton, “The Role of Magnesium in Neurological Disorders,” Nutrients 10, no. 6 (June 6, 2018): e730. Emily K. Tarleton et al., “Role of Magnesium Supplementation in the Treatment of Depression: A Randomized Clinical Trial,” PLOS One 12, no. 6 (June 27, 2017): e0180067.
418
Evert Boonstra et al., “Neurotransmitters as Food Supplements: The Effects of GABA on Brain and Behavior,” Frontiers in Psychology 6 (2015): 1520.
419
A. M. Abdou et al., “Relaxation and Immunity Enhancement Effects of Gammaaminobutyric Acid (GABA) Administration in Humans,” BioFactors 26, no. 3 (2006): 201-8.
420
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 185-86.
421
Там же.
422
“HIV/AIDS and Mental Health,” National Institute of Mental Health, last revised November 2016, https://www.nimh.nih.gov/health/topics/hiv-aids/index.shtml.
423
Nian-Sheng Tzeng et al., “Increased Risk of Psychiatric Disorders in Allergic Diseases: A Nationwide, Population-Based, Cohort Study,” Frontiers in Psychiatry 9 (April 24, 2018): 133.
424
Yi-Hao Peng et al., “Adult Asthma Increases Dementia Risk: A Nationwide Cohort Study,” Journal of Epidemiology and Community Health 69, no. 2 (February 2015): 123-28. Minna Rusanen et al., “Chronic Obstructive Pulmonary Disease and Asthma and the Risk of Mild Cognitive Impairment and Dementia: A Population Based CAIDE Study,” Current Alzheimer Research 10, no. 5 (June 2013): 549-55.
425
Ora Nakash et al., “Comorbidity of Common Mental Disorders with Cancer and Their Treatment Gap: Findings from the World Mental Health Surveys,” Psycho-Oncology 23, no. 1 (January 2014): 40–51.
426
William F. Pirl, “Evidence Report on the Occurrence, Assessment, and Treatment of Depression in Cancer Patients,” JNCI Monographs 2004, no. 32 (July 2004): 32–39.
427
“Women & Autoimmunity,” American Autoimmune Related Diseases Association, accessed August 15, 2019, https://www.aarda.org/who-we-help/patients/women-and-autoimmunity/.
428
Marc Malkin, “Lady Gaga Opens Up about Her ‘Mental Health Crisis,’” Variety, November 9, 2018, https://variety.com/2018/scene/news/lady-gaga-mental-health-struggles-1203023093/.
429
Michael E. Benros et al., “Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study,” JAMA Psychiatry 70, no. 8 (August 2013): 812-20. Gianluca Bagnato et al., “Comparation of Levels of Anxiety and Depression in Patients with Autoimmune and Chronic-Degenerative Rheumatic: Preliminary Data,” Reumatismo (Italian) 58, no. 3 (July – September 2006): 206-11.
430
William W. Eaton et al., “Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers,” American Journal of Psychiatry 163, no. 3 (March 2006): 521-28.
431
Joshua D. Rosenblat and Roger S. McIntyre, “Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications,” Brain Sciences 7, no. 11 (October 30, 2017): e144.
432
Philip Rising Nielsen, Michael Eriksen Benros, and Søren Dalsgaard, “Associations between Autoimmune Diseases and Attention-Deficit/Hyperactivity Disorder: A Nationwide Study,” Journal of the American Academy of Child and Adolescent Psychiatry 56, no. 3 (March 2017): 234-40.e1.
433
Clare J. Wotton and Michael J. Goldacre, “Associations between Specific Autoimmune Diseases and Subsequent Dementia: Retrospective Record-Linkage Cohort Study, UK,” Journal of Epidemiology and Community Health 71, no. 6 (June 2017): 576-83.
434
Amen, Memory Rescue, 188.
435
Ole Köhler-Forsberg et al., “A Nationwide Study in Denmark of the Association between Treated Infections and the Subsequent Risk of Treated Mental Disorders in Children and Adolescents,” JAMA Psychiatry 76, no. 3 (March 2019): 271-79.
436
Michael E. Benros et al., “Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders: A Nationwide Study,” JAMA Psychiatry 70, no. 8 (August 2013): 812-20.
437
Amen, Memory Rescue, 189.
438
R. A. Underhill, “Myalgic Encephalomyelitis, Chronic Fatigue Syndrome: An Infectious Disease,” Medical Hypotheses 85, no. 6 (December 2015): 765-73.
439
Z. Marinković and S. Dukić, “Historical and Medical Review of Syphilis-Afflicted Army Leaders, Rulers and Statesmen,” Medicinski Pregled 64, nos. 7–8 (July/August 2011): 423-27.
440
Lucas Lonardoni Crozatti et al., “Atypical Behavioral and Psychiatric Symptoms: Neurosyphilis Should Always Be Considered,” Autopsy Case Reports 5, no. 3 (July-September 2015): 43–47.
441
Ruth F. Itzhaki et al., “Microbes and Alzheimer’s Disease,” Journal of Alzheimer’s Disease 51, no. 4 (2016): 979-84.
442
James S. Brown Jr., “Geographic Correlation of Schizophrenia to Ticks and Tick-Borne Encephalitis,” Schizophrenia Bulletin 20, no. 4 (1994): 755-75; использовано с разрешения.
443
4 Ying Qiang Xiang et al., “Adjunctive Minocycline for Schizophrenia: A Meta-analysis of Randomized Controlled Trials,” European Neuropsychopharmacology 27, no. 1 (January 2017): 8-18.
444
Amen, Memory Rescue, 192.
445
“Toxoplasmosis Frequently Asked Questions (FAQs),” Centers for Disease Control and Prevention, last reviewed September 28, 2018, https://www.cdc.gov/parasites/toxoplasmosis/gen_info/faqs.html.
446
Claudia Del Grande et al., “Is Toxoplasma gondii a Trigger of Bipolar Disorder?” Pathogens 6, no. 1 (March 2017): e3.
447
Jaana Suvisaari et al., “Toxoplasma gondii Infection and Common Mental Disorders in the Finnish General Population,” Journal of Affective Disorders 223 (December 1, 2017): 20–25.
448
C. J. Carter, “Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders,” Journal of Pathogens 2013 (2013): 965046.
449
Ed Yong, “Zombie Roaches and Other Parasite Tales,” TED Talk, March 2014, video, 13:02, https://www.ted.com/talks/ed_yong_suicidal_wasps_zombie_roaches_and_other_tales_of_parasites.
450
“What Is PANS?” Moleculera Labs, accessed August 16, 2019, https://www.moleculeralabs.com/what-is-pans/
451
O. Köhler et al., “Infections and Exposure to Anti-infective Agents and the Risk of Severe Mental Disorders: A Nationwide Study,” Acta Psychiatrica Scandinavica 135, no. 2 (February 2017): 97-105.
452
Emily G. Severance et al., “Candida albicans Exposures, Sex Specificity and Cognitive Deficits in Schizophrenia and Bipolar Disorder,” npj Schizophrenia 2 (May 4, 2016): 16018.
453
Emily Severance, quoted at “Yeast Infection Linked to Mental Illness,” Johns Hopkins Medicine, May 4, 2016, https://www.hopkinsmedicine.org/news/media/releases/yeast_infection_linked_to_mental_illness
454
Yifan Wu et al., “Microglia and Amyloid Precursor Protein Coordinate Control of Transient Candida Cerebritis with Memory Deficits,” Nature Communications 10, no. 1 (January 4, 2019): 58.
455
Adit A. Ginde, Mark C. Liu, and Carlos A. Camargo Jr., “Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988–2004,” Archives of Internal Medicine 169, no. 6 (March 23, 2009): 626-32.
456
Amen, Memory Rescue, 194.
457
Frederic Blanc et al., “Lyme Neuroborreliosis and Dementia,” Journal of Alzheimer’s Disease 41, no. 4 (2014): 1087-93.
458
Justin C. McArthur, “HIV Dementia: An Evolving Disease,” Journal of Neuroimmunology 157, nos. 1–2 (December 2004): 3-10.
459
Judith Miklossy, “Historic Evidence to Support a Causal Relationship between Spirochetal Infections and Alzheimer’s Disease,” Frontiers in Aging Neuroscience 7 (April 16, 2015): 46.
460
Steven A. Harris and Elizabeth A. Harris, “Herpes Simplex Virus Type 1 and Other Pathogens Are Key Causative Factors in Sporadic Alzheimer’s Disease,” Journal of Alzheimer’s Disease 48, no. 2 (2015): 319-53. Ariah J. Steel and Guy D. Eslick, “Herpes Viruses Increase the Risk of Alzheimer’s Disease: A Meta-Analysis,” Journal of Alzheimer’s Disease 47, no. 2 (2015): 351-64.
461
Lisa L. Barnes et al., “Cytomegalovirus Infection and Risk of Alzheimer Disease in Older Black and White Individuals,” Journal of Infectious Diseases 211, no. 2 (January 15, 2015): 230-37.
462
S. M. Shim et al., “Elevated Epstein-Barr Virus Antibody Level Is Associated with Cognitive Decline in the Korean Elderly,” Journal of Alzheimer’s Disease 55, no. 1 (2017): 293–301.
463
Mahmoud Mahami-Oskouei et al., “Toxoplasmosis and Alzheimer: Can Toxoplasma gondii Really Be Introduced as a Risk Factor in Etiology of Alzheimer?” Parasitology Research 115, no. 8 (August 2016): 3169-74.
464
Tali Shindler-Itskovitch et al., “A Systematic Review and Meta-Analysis of the Association between Helicobacterpylori Infection and Dementia,” Journal of Alzheimer’s Disease 52, no. 4 (2016): 1431-42.
465
Priya Maheshwari and Guy D. Eslick, “Bacterial Infection and Alzheimer’s Disease: A Meta-analysis,” Journal of Alzheimer’s Disease 43, no. 3 (2015): 957-66.
466
Brunetta Porcelli et al., “Association between Stressful Life Events and Autoimmune Diseases: A Systematic Review and Meta-analysis of Retrospective Case-Control Studies,” Autoimmunity Reviews 15, no. 4 (April 2016): 325-34. A. Matos-Santos et al., “Relationship between the Number and Impact of Stressful Life Events and the Onset of Graves’ Disease and Toxic Nodular Goitre,” Clinical Endocrinology (Oxford) 55, no. 1 (July 2001): 15–19. David C. Mohr et al., “Association between Stressful Life Events and Exacerbation in Multiple Sclerosis: A Meta-analysis,” BMJ 328 (March 27, 2004): 731.
467
Lee S. Berk et al., “Modulation of Neuroimmune Parameters during the Eustress of Humor-Associated Mirthful Laughter,” Alternative Therapies in Health and Medicine 7, no. 2 (March 2001): 62–72, 74–76. Kyung Hee Ryu, Hye Sook Shin, and Eun Young Yang, “Effects of Laughter Therapy on Immune Responses in Postpartum Women,” Journal of Alternative and Complementary Medicine 21, no. 12 (December 2015): 781-88. Norman Cousins, “Anatomy of an Illness (as Perceived by the Patient),” New England Journal of Medicine 295, no. 26 (December 23, 1976): 1458-63.
468
S. P. Wasser, “Medicinal Mushrooms as a Source of Antitumor and Immunomodulating Polysaccharides,” Applied Microbiology and Biotechnology 60, no. 3 (November 2002): 258-74.50. Peter Roupas et al., “The Role of Edible Mushrooms in Health: Evaluation of the Evidence,” Journal of Functional Foods 4, no. 4 (October 2012): 687–709. Seema Patel and Arun Goyal, “Recent Developments in Mushrooms as Anti-cancer Therapeutics: A Review,” 3 Biotech 2, no. 1 (March 2012): 1-15. Lu Ren, Conrad Perera, and Yacine Hemar, “Antitumor Activity of Mushroom Polysaccharides: A Review,” Food and Function 3, no. 11 (November 2012): 1118-30. Dhanushka Gunawardena et al., “Anti-inflammatory Effects of Five Commercially Available Mushroom Species Determined in Lipopolysaccharide and Interferon-γ Activated Murine Macrophages,” Food Chemistry 148 (April 1, 2014): 92–96.
469
Mayumi Nagano et al., “Reduction of Depression and Anxiety by 4 Weeks Hericium erinaceus Intake,” Biomedical Research 31, no. 4 (August 2010): 231-37.
470
Koichiro Mori et al., “Improving Effects of the Mushroom Yamabushitake (Hericium erinaceus) on Mild Cognitive Impairment: A Double-Blind Placebo-Controlled Clinical Trial,” Phytotherapy Research 23, no. 3 (March 2009): 367-72.
471
Xiaoshuang Dai et al., “Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults,” Journal of the American College of Nutrition 34, no. 6 (2015): 478-87. Mary Jo Feeney et al., “Mushrooms and Health Summit Proceedings,” Journal of Nutrition 144, no. 7 (July 2014): 1128S-36S. J. M. Gaullier et al., “Supplementation with a Soluble β-glucan Exported from Shiitake Medicinal Mushroom, Lentinus edodes (Berk.) Singer Mycelium: A Crossover, Placebo-Controlled Study in Healthy Elderly,” International Journal of Medicinal Mushrooms 13, no. 4 (2011): 319-26.
472
B. S. Sanodiya et al., “Ganoderma lucidum: A Potent Pharmacological Macrofungus,” Current Pharmaceutical Biotechnology 10, no. 8 (December 2009): 717-42. Hong Zhao et al., “Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial,” Evidence-Based Complementary and Alternative Medicine 2012 (2012): 809614.
473
Xing-Tai Li et al., “Protective Effects on Mitochondria and Anti-aging Activity of Polysaccharides from Cultivated Fruiting Bodies of Cordyceps militaris,” American Journal of Chinese Medicine 38, no. 6 (2010): 1093-106.
474
Amen, Memory Rescue, 197. 57. Susan S. Percival, “Aged Garlic Extract Modifies Human Immunity,” Journal of Nutrition 146, no. 2 (February 2016): 433S-36S. Craig S. Charron et al., “A Single Meal Containing Raw, Crushed Garlic Influences Expression of Immunity-and Cancer-Related Genes in Whole Blood of Humans,” Journal of Nutrition 145, no. 11 (November 2015): 2448-55.
475
Cheryl A. Rowe et al., “Regular Consumption of Concord Grape Juice Benefits Human Immunity,” Journal of Medicinal Food 14, nos. 1–2 (January/February 2011): 69–78. Susan J. Zunino, “Type 2 Diabetes and Glycemic Response to Grapes or Grape Products,” Journal of Nutrition 139, no. 9 (September 2009): 1794S-1800S. M. P. Nantz et al., “Immunity and Antioxidant Capacity in Humans Is Enhanced by Consumption of a Dried, Encapsulated Fruit and Vegetable Juice Concentrate,” Journal of Nutrition 136, no. 10 (October 2006): 2606-610.
476
Marlies Karsch-Völk et al., “Echinacea for Preventing and Treating the Common Cold,” Cochrane Database of Systematic Reviews, no. 2 (February 20, 2014): CD000530. Keith I. Block and Mark N. Mead, “Immune System Effects of Echinacea, Ginseng, and Astragalus: A Review,” Integrative Cancer Therapies 2, no. 3 (September 2003): 247-67.
477
Angélica T. Vieira, Mauro M. Teixeira, and Flaviano S. Martins, “The Role of Probiotics and Prebiotics in Inducing Gut Immunity,” Frontiers in Immunology 4 (December 12, 2013): 445. Rohit Sharma et al., “Dietary Supplementation of Milk Fermented with Probiotic Lactobacillus fermentum Enhances Systemic Immune Response and Antioxidant Capacity in Aging Mice,” Nutrition Research (New York) 34, no. 11 (November 2014): 968-81.
478
Chad Robertson, “The Link between Vitamin C and Optimal Immunity,” Life Extension magazine, November 2015, https://www.lifeextension.com/magazine/2015/11/the-link-between-vitamin-c-and-optimal-immunity/page-01. M. de la Fuente et al., “Immune Function in Aged Women Is Improved by Ingestion of Vitamins C and E,” Canadian Journal of Physiology and Pharmacology 76, no. 4 (1998): 373-80.
479
J. Rodrigo Mora, Makoto Iwata, and Ulrich H. von Andrian, “Vitamin Effects on the Immune System: Vitamins A and D Take Centre Stage,” Nature Reviews Immunology 8, no. 9 (September 2008): 685-98. Cynthia Aranow, “Vitamin D and the Immune System,” Journal of Investigative Medicine 59, no. 6 (August 2011): 881-86. Oregon State University, “Key Feature of Immune System Survived in Humans, Other Primates for 60 Million Years,” EurekAlert! American Association for the Advancement of Science, August 18, 2009, https://www.eurekalert.org/pub_releases/2009-08/osu-kfo081809.php. Mitsuyoshi Urashima et al., “Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza A in Schoolchildren,” American Journal of Clinical Nutrition 91, no. 5 (May 2010): 1255-60.
480
Satoru Moriguchi and Mikako Muraga, “Vitamin E and Immunity,” Vitamins and Hormones 59 (2000): 305-36.
481
Junaidah B. Barnett et al., “Effect of Zinc Supplementation on Serum Zinc Concentration and T cell Proliferation in Nursing Home Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial,” American Journal of Clinical Nutrition 103, no. 3 (March 2016): 942-51. Laura Kahmann et al., “Effect of Improved Zinc Status on T helper Cell Activation and TH1/TH2 Ratio in Healthy Elderly Individuals,” Biogerontology 7, nos. 5–6 (October – December 2006): 429-35. Ananda S. Prasad et al., “Effect of Zinc Supplementation on Incidence of Infections and Hospital Admissions in Sickle Cell Disease (SCD),” American Journal of Hematology 61, no. 3 (July 1999): 194–202.
482
Jorge Correale, María Célica Ysrraelit, and María Inés Gaitán, “Immunomodulatory Effects of Vitamin D in Multiple Sclerosis,” Brain 132, part 5 (May 2009): 1146-60.
483
См. “835 Abstracts with Vitamin D Research,” Vitamin D, GreenMedInfo, accessed August 16, 2019, https://www.greenmedinfo.com/substance/vitamin-d.
484
Herbert W. Harris et al., “Vitamin D Deficiency and Psychiatric Illness,” Current Psychiatry 12, no. 4 (April 2013): 18–27.
485
Paul Knekt et al., “Serum 25-hydroxyvitamin D Concentration and Risk of Dementia,” Epidemiology (Cambridge, MA) 25, no. 6 (November 2014): 799–804.
486
Rathish Nair and Arun Maseeh, “Vitamin D: The ‘Sunshine’ Vitamin,” Journal of Pharmacology and Pharmacotherapeutics 3, no. 2 (April – June 2012): 118-26.
487
R. Jorde et al., “Effects of Vitamin D Supplementation on Symptoms of Depression in Overweight and Obese Subjects: Randomized Double Blind Trial,” Journal of Internal Medicine 264, no. 6 (December 2008): 599–609.
488
Albina Nowak et al., “Effect of Vitamin D3 on Self-Perceived Fatigue: A Double-Blind Randomized Placebo-Controlled Trial,” Medicine (Baltimore) 95, no. 52 (December 2016): e5353.
489
Adit A. Ginde, Mark C. Liu, and Carlos A. Camargo Jr., “Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988–2004,” Archives of Internal Medicine 169, no. 6 (2009): 626-32.
490
Amen, Memory Rescue, 198-99.
491
E. Sohl et al., “The Impact of Medication on Vitamin D Status in Older Individuals,” European Journal of Endocrinology 166, no. 3 (March 2012): 477-85.
492
Phillip A. Engen et al., “The Gastrointestinal Microbiome: Alcohol Effects on the Composition of Intestinal Microbiota,” Alcohol Research: Current Reviews 37, no. 2 (2015): 223-36.
493
Mark L. Gordon, Traumatic Brain Injury: A Clinical Approach to Diagnosis and Treatment (Los Angeles: Millennium Health Centers, 2016).
494
Mark L. Gordon, “ISNR Keynote Speaker Mark L. Gordon 2015,” Andrew Marr, December 25, 2016, video, 1:00:12, https://www.youtube.com/watch?v=Q_Uu-soMavQ&feature=youtu.be.
495
J. McGaffee, M. A. Barnes, and S. Lippmann, “Psychiatric Presentations of Hypothyroidism,” American Family Physician 23, no. 5 (May 1, 1981): 129-33.
496
Thomas W. Heinrich and Garth Grahm, “Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited,” Primary Care Companion to the Journal of Clinical Psychiatry 5, no. 6 (December 2003): 260-66.
497
P. C. Whybrow, A. J. Prange Jr., and C. R. Treadway, “Mental Changes Accompanying Thyroid Gland Dysfunction: A Reappraisal Using Objective Psychological Measurement,” Archives of General Psychiatry 20, no. 1 (1969): 48–63.
498
Thomas D. Geracioti Jr., “Identifying Hypothyroidism’s Psychiatric Presentations,” Current Psychiatry 5, no. 11 (November 2006): 98-117. Nadine Correia Santos et al., “Revisiting Thyroid Hormones in Schizophrenia,” Journal of Thyroid Research 2012 (2012): 569147.
499
Jeffrey Garber, et al., “Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association,” Endocrine Practice 18, no. 6 (November 2012): 988-1028.
500
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
501
Heinrich and Grahm, “Hypothyroidism Presenting as Psychosis,” 260-66.
502
John J. Haggerty Jr., Dwight L. Evans, Arthur J. Prange Jr., “Organic Brain Syndrome Associated with Marginal Hypothyroidism,” American Journal of Psychiatry 143, no. 6 (June 1986): 785-86.
503
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
504
“Hyperthyroidism (Overactive Thyroid),” National Institute of Diabetes and Digestive and Kidney Diseases, August 2016, https://www.niddk.nih.gov/health-information/endocrine-diseases/hyperthyroidism.
505
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
506
S. Chetty et al., “Stress and Glucocorticoids Promote Oligodendrogenesis in the Adult Hippocampus,” Molecular Psychiatry 19, no. 12 (December 2014): 1275-83.
507
Там же.
508
Camilla A. M. Glad et al., “Reduced DNA Methylation and Psychopathology following Endogenous Hypercortisolism – A Genome-Wide Study,” Scientific Reports 7 (2017): 44445.
509
Paul Ardayfio and Kwang-Soo Kim, “Anxiogenic-Like Effect of Chronic Corticosterone in the Light-Dark Emergence Task in Mice,” Behavioral Neuroscience 120, no. 2 (2006): 249-56.
510
Sarah Khan and Rafeeq Alam Khan, “Chronic Stress Leads to Anxiety and Depression,” Annals of Psychiatry and Mental Health 5, no. 1 (January 2017): 1091.
511
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 208.
512
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
513
Amen, Memory Rescue, 210.
514
Claudia Barth, Arno Villringer, and Julia Sacher, “Sex Hormones Affect Neurotransmitters and Shape the Adult Female Brain during Hormonal Transition Periods,” Frontiers in Neuroscience 9 (2015): 37.
515
Linda A. Bean, Lara Ianov, and Thomas C. Foster, “Estrogen Receptors, the Hippocampus, and Memory,” Neuroscientist 20, no. 5 (October 2014): 534-45.
516
Laila Adly et al., “Serum Concentrations of Estrogens, Sex Hormone-Binding Globulin, and Androgens and Risk of Breast Cancer in Postmenopausal Women,” International Journal of Cancer 119, no. 10 (November 15, 2006): 2402-7.
517
Silvia Deandrea et al., “Alcohol and Breast Cancer Risk Defined by Estrogen and Progesterone Receptor Status: A Case-Control Study,” Cancer Epidemiology, Biomarkers and Prevention 17, no. 8 (August 2008): 2025-28.
518
Samantha S. Solden et al., “Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol,” Journal of Immunology 171, no. 11 (December 1, 2003): 6267-74.
519
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
520
Там же.
521
Loyola University Health System, “Increased Stroke Risk from Birth Control Pills, Review Finds,” ScienceDaily, October 27, 2009, https://www.sciencedaily.com/releases/2009/10/091026152820.htm.
522
Belinda A. Pletzer and Hubert H. Kerschbaum, “50 Years of Hormonal Contraception – Time to Find Out, What It Does to Our Brain,” Frontiers in Neuroscience 8 (August 21, 2014): 256.
523
Charlotte Weissel Skovlund et al., “Association of Hormonal Contraception with Depression,” JAMA Psychiatry 73, no. 11 (November 2016): 1154-62.
524
G. B. Slap, “Oral Contraceptives and Depression: Impact, Prevalence and Cause,” Journal of Adolescent Health Care 2, no. 11 (September 1981): 53–64.
525
William V. Williams, “Hormonal Contraception and the Development of Autoimmunity: A Review of the Literature,” Linacre Quarterly 84, no. 3 (August 2017): 275-95.
526
Johannes Hertel et al., “Evidence for Stress-Like Alterations in the HPA-Axis in Women Taking Oral Contraceptives,” Scientific Reports 7, no. 1 (October 26, 2017): 14111.
527
Y. Zimmerman et al., “The Effect of Combined Oral Contraception on Testosterone Levels in Healthy Women: A Systematic Review and Meta-analysis,” Human Reproduction Update 20, no. 1 (January/February 2014): 76-105.
528
Claudia Panzer et al., “Impact of Oral Contraceptives on Sex Hormone-Binding Globulin and Androgen Levels: A Retrospective Study in Women with Sexual Dysfunction,” Journal of Sexual Medicine 3, no. 1 (January 2006): 104-13.
529
Hamed Khalili, “Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions,” Drug Safety 39, no. 3 (March 2016): 193-97.
530
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
531
Carlo Pergola et al., “Testosterone Suppresses Phospholipase D, Causing Sex Differences in Leukotriene Biosynthesis in Human Monocytes,” FASEB Journal 25, no. 10 (October 2011): 3377-87. Амен, Д. Загадки женского мозга. – Эксмо, 2014.
532
Linnea Hergot Berglund et al., “Testosterone Levels and Psychological Health Status in Men from a General Population: The Tromsø Study,” Aging Male 14, no. 1 (March 2011): 37–41.
533
Amen, Memory Rescue, 216.
534
Амен, Д. Загадки женского мозга. (Эксмо, 2014).
535
Lu Sun et al., “Meta-Analysis Suggests That Smoking Is Associated with an Increased Risk of Early Natural Menopause,” Menopause (New York) 19, no. 2 (February 2012): 126-32.
536
Ana M. Fernández-Alonso et al., “Obesity Is Related to Increased Menopausal Symptoms among Spanish Women,” Menopause International 16, no. 3 (September 2010): 105-10.
537
Reini W. Bretveld et al., “Pesticide Exposure: The Hormonal Function of the Female Reproductive System Disrupted?” Reproductive Biology and Endocrinology 4 (May 31, 2006): 30.
538
Amen, Memory Rescue, 220.
539
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
540
Thomas T. Y. Wang et al., “Estrogen Receptor Alpha as a Target for Indole-3-Carbinol,” Journal of Nutritional Biochemistry 17, no. 10 (October 2006): 659-64.
541
Gregory A. Reed et al., “A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects,” Cancer Epidemiology, Biomarkers and Prevention 14, no. 8 (2005): 1953-60.
542
E. Sherwood Brown et al., “A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression,” Neuropsychopharmacology 39, no. 12 (November 2014): 2867-73.
543
C. E. Marx et al., “Pregnenolone as a Novel Therapeutic Candidate in Schizophrenia: Emerging Preclinical and Clinical Evidence,” Neuroscience 191 (September 15, 2011): 78–90.
544
Nicole Ducharme et al., “Brain Distribution and Behavioral Effects of Progesterone and Pregnenolone after Intranasal or Intravenous Administration,” European Journal of Pharmacology 641, nos. 2–3 (September 1, 2010): 128-34.
545
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
546
Amen, Memory Rescue, 221.
547
* Его еще называют диабетическим ожирением. – Прим. науч. ред.
548
Cyrus A. Raji et al., “Brain Structure and Obesity,” Human Brain Mapping 31, no. 3 (March 2010): 353-64.
549
Социальная сеть, запрещенная на территории РФ.
550
Andy Menke et al., “Prevalence of and Trends in Diabetes among Adults in the United States, 1988–2012,” JAMA 314, no. 10 (2015): 1021-29.
551
“Adult Obesity Facts,” Overweight and Obesity, Centers for Disease Control and Prevention, last reviewed August 13, 2018, https://www.cdc.gov/obesity/data/adult.html.
552
Gregory E. Simon et al., “Association between Obesity and Psychiatric Disorders in the US Adult Population,” Archives of General Psychiatry 63, no. 7 (July 2006): 824-30. Nancy M. Petry et al., “Overweight and Obesity Are Associated with Psychiatric Disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions,” Psychosomatic Medicine 70, no. 3 (April 2008): 288-97.
553
H. C. M. Byrd, C. Curtin, and S. E. Anderson, “Attention-Deficit/Hyperactivity Disorder and Obesity in US Males and Females, Age 8-15 Years: National Health and Nutrition Examination Survey 2001–2004,” Pediatric Obesity 8, no. 6 (December 2013): 445-53.
554
Michael Hinck, “How Obesity Can Affect Your Teen’s Self Esteem,” Health Beat, Jamaica Hospital Medical Center, September 26, 2014, https://jamaicahospital.org/newsletter /how-obesity-can-affect-your-teens-self-esteem/.
555
Zhang Xue-Yan et al., “Obese Chinese Primary-School Students and Low Self-Esteem: A Cross-Sectional Study,” Iranian Journal of Pediatrics 26, no. 4 (August 2016): e3777.
556
Kenneth M. Carpenter et al., “Relationships between Obesity and DSM-IV Major Depressive Disorder, Suicide Ideation, and Suicide Attempts: Results from a General Population Study,” American Journal of Public Health 90, no. 2 (2000): 251-57.
557
Cyrus A. Raji et al., “Brain Structure and Obesity,” Human Brain Mapping 31, no. 3 (March 2010): 353-64. Kristen C. Willeumier, Derek V. Taylor, and Daniel G. Amen, “Elevated BMI Is Associated with Decreased Blood Flow in the Prefrontal Cortex Using SPECT Imaging in Healthy Adults,” Obesity (Silver Spring, MD) 19, no. 5 (May 2011): 1095-97. Mark Hamer, G. David Batty, “Association of Body Mass Index and Waist-to-Hip Ratio with Brain Structure,” Neurology 92, no. 6 (February 2019): e594-600.
558
Alan R. Schwartz et al., “Obesity and Obstructive Sleep Apnea: Pathogenic Mechanisms and Therapeutic Approaches,” Proceedings of the American Thoracic Society 5, no. 2 (2008): 185-92.
559
J. M. Zanoveli et al., “Depression Associated with Diabetes: From Pathophysiology to Treatment,” Current Diabetes Reviews 12, no. 3 (2016): 165-78. A. M. Castellano-Guerrero et al., “Prevalence and Predictors of Depression and Anxiety in Adult Patients with Type 1 Diabetes in Tertiary Care Setting,” Acta Diabetologica 55, no. 9 (September 2018): 943-53.
560
Hirokatsu Niwa et al., “Clinical Analysis of Cognitive Function in Diabetic Patients by MMSE and SPECT,” Diabetes Research and Clinical Practice 72, no. 2 (May 2006): 142-47. J. F. Jimenez-Bonilla et al., “Assessment of Cerebral Blood Flow in Diabetic Patients with No Clinical History of Neurological Disease,” Nuclear Medicine Communications 17, no. 9 (September 1996): 790-94.
561
F. Pasquier et al., “Diabetes Mellitus and Dementia,” Diabetes and Metabolism 32, no. 5, part 1 (November 2006): 403-14. Kapil Gudala et al., “Diabetes Mellitus and Risk of Dementia: A Meta-analysis of Prospective Observational Studies,” Journal of Diabetes Investigation 4, no. 6 (November 2013): 640-50.
562
Ewa Racicka and Anita Brynska, “Eating Disorders in Children and Adolescents with Type 1 and Type 2 Diabetes: Prevalance, Risk Factors, Warning Signs,” Psychiatria Polska 49, no. 5 (2015): 1017-24.
563
Syudo Yamasaki et al., “Maternal Diabetes in Early Pregnancy, and Psychotic Experiences and Depressive Symptoms in 10-Year-Old Offspring: A Population-Based Birth Cohort Study,” Schizophrenia Research 206 (April 2019): 52–57.
564
Monique Aucoin and Sukriti Bhardwaj, “Generalized Anxiety Disorder and Hypoglycemia Symptoms Improved with Diet Modification,” Case Reports in Psychiatry 2016 (2016): 7165425.
565
Там же.
566
Malcolm Peet, “International Variations in the Outcome of Schizophrenia and the Prevalence of Depression in Relation to National Dietary Practices: An Ecological Analysis,” British Journal of Psychiatry 184, no. 5 (May 2004): 404-8.
567
“Type 1 Diabetes Low Blood Sugar Symptoms,” JDRF, accessed August 19, 2019, https://www.jdrf.org/t1d-resources/about/symptoms/low-blood-sugar/.
568
Peter Bongiorno, “Is There a Blood Sugar Monster Lurking within You?” Psychology Today, November 13, 2014, https://www.psychologytoday.com/us/blog/inner-source /201311/is-there-blood-sugar-monster-lurking-within-you.
569
Belinda S. Lennerz et al., “Effects of Dietary Glycemic Index on Brain Regions Related to Reward and Craving in Men,” American Journal of Clinical Nutrition 98, no. 3 (September 2013): 641-47.
570
“Type 1 Diabetes,” JDRF.
571
Chris E. Zwilling et al., “Nutrient Biomarker Patterns, Cognitive Function, and fMRI Measures of Network Efficiency in the Aging Brain,” NeuroImage 188 (March 2019): 239-51.
572
E. Duron and Olivier Hanon, “Vascular Risk Factors, Cognitive Decline, and Dementia,” Vascular Health and Risk Management 4, no. 2 (2008): 363-81.
573
Rachel A. Whitmer, “The Epidemiology of Adiposity and Dementia,” Current Alzheimer Research 4, no. 2 (April 2007): 117-22. Duron and Hanon, “Vascular Risk Factors.”
574
Jaakko Tuomilehto et al., “Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance,” New England Journal of Medicine 344, no. 18 (May 3, 2001): 1343-50.
575
Julie C. Antvorskov et al., “Association between Maternal Gluten Intake and Type 1 Diabetes in Offspring: National Prospective Cohort Study in Denmark,” BMJ 362 (September 19, 2018): k3547.
576
Daniel G. Amen and Tana Amen, The Brain Warrior’s Way (New York: New American Library, 2016), 1, 28.
577
Associated Press, “450 Sheep Jump to Their Deaths in Turkey,” USA Today, July 8, 2005, http://usatoday30.usatoday.com/news/offbeat/2005-07-08-sheep-suicide_x.htm.
578
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 235-36.
579
Andrew Reynolds et al., “Carbohydrate Quality and Human Health: A Series of Systematic Reviews and Meta-analyses,” Lancet 393, no. 10170 (February 2, 2019): 434-45.
580
Cornell University, “Weighing Yourself Daily Can Tip the Scale in Your Favor,” ScienceDaily, June 17, 2015, https://www.sciencedaily.com/releases/2015/06/150617134622.htm.
581
Chun-Ju Chiang et al., “Midlife Risk Factors for Subtypes of Dementia: A Nested CaseControl Study in Taiwan,” American Journal of Geriatric Psychiatry 15, no. 9 (September 2007): 762-71. Heidi White et al., “Weight Change in Alzheimer’s Disease,” Journal of the American Geriatrics Society 44, no. 3 (March 1996): 265-72.
582
Eric J. Shiroma et al., “Strength Training and the Risk of Type 2 Diabetes and Cardiovascular Disease,” Medicine and Science in Sports and Exercise 49, no. 1 (January 2017): 40–46.
583
Frank B. Hu et al., “Walking Compared with Vigorous Physical Activity and Risk of Type 2 Diabetes in Women: A Prospective Study,” JAMA 282, no. 15 (1999): 1433-39.
584
Carl J. Caspersen and Janet E. Fulton, “Epidemiology of Walking and Type 2 Diabetes,” Medicine and Science in Sports and Exercise 40, suppl. 7 (July 2008): S519-S528.
585
Amen, Memory Rescue, 236.
586
Там же.
587
Artemis P. Simopoulos, “Dietary Omega-3 Fatty Acid Deficiency and High Fructose Intake in the Development of Metabolic Syndrome, Brain Metabolic Abnormalities, and Nonalcoholic Fatty Liver Disease,” Nutrients 5, no. 8 (July 26, 2013): 2901-23.
588
Luc Djoussé et al., “Plasma Omega-3 Fatty Acids and Incident Diabetes in Older Adults,” American Journal of Clinical Nutrition 94, no. 2 (August 2011): 527-33.
589
Shokouh Sarbolouki et al., “Eicosapentaenoic Acid Improves Insulin Sensitivity and Blood Sugar in Overweight Type 2 Diabetic Mellitus Patients: A Double-Blind Randomized Clinical Trial,” Singapore Medical Journal 54, no. 7 (2013): 387-90.
590
Kimberly A. Brownley et al., “A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Binge Eating Disorder: Results of the Binge Eating and Chromium (BEACh) Study,” Journal of Psychosomatic Research 75, no. 1 (July 2013): 36–42.
591
N. Suksomboon, N. Poolsup, and A. Yuwanakorn, “Systematic Review and Meta-analysis of the Efficacy and Safety of Chromium Supplementation in Diabetes,” Journal of Clinical Pharmacy and Therapeutics 39, no. 3 (2014): 292–306. H. Rabinovitz et al., “Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Type 2 Diabetes Mellitus Elderly Patients,” International Journal for Vitamin and Nutrition Research 74, no. 3 (2004): 178-82.
592
Amen, Memory Rescue, 237.
593
Ting Lu et al., “Cinnamon Extract Improves Fasting Blood Glucose and Glycosylated Hemoglobin in Chinese Patients with Type 2 Diabetes,” Nutrition Research (New York) 32, no. 6 (June 2012): 408-12. Paul A. Davis and Wallace Yokoyama, “Cinnamon Intake Lowers Fasting Blood Glucose: Meta-Analysis,” Journal of Medicinal Food 14, no. 9 (September 2011): 884-89. Ashley Magistrelli and Jo Carol Chezem, “Effect of Ground Cinnamon on Postprandial Blood Glucose Concentration in Normal-Weight and Obese Adults,” Journal of the Academy of Nutrition and Dietetics 112, no. 11 (November 2012): 1806-9. Ashley N. Hoehn and Amy L. Stockert, “The Effects of Cinnamomum cassia on Blood Glucose Values Are Greater Than Those of Dietary Changes Alone,” Nutrition and Metabolic Insights 5 (2012): 77–83.
594
Mark L. Wahlqvist et al., “Cinnamon Users with Prediabetes Have a Better Fasting Working Memory: A Cross-Sectional Function Study,” Nutrition Research (New York) 36, no. 4 (April 2016): 305-10.
595
Robert Krikorian et al., “Improved Cognitive-Cerebral Function in Older Adults with Chromium Supplementation,” Nutritional Neuroscience 13, no. 3 (2010): 116-22.
596
“Sleep and Sleep Disorder Statistics,” American Sleep Association, accessed August 20, 2019, https://www.sleepassociation.org/about-sleep/sleep-statistics/.
597
Там же.
598
“Sleep and Mental Health,” Harvard Health Publishing, Harvard Medical School, updated March 18, 2019, http://www.health.harvard.edu/newsletter_article/sleep-and-mental-health.
599
“Sleep Disorders: The Connection between Sleep and Mental Health,” National Alliance on Mental Illness, accessed August 20, 2019, https://www.nami.org/Learn-More/Mental-Health-Conditions/Related-Conditions/sleep-disorders.
600
David Nutt, Sue Wilson, and Louise Paterson, “Sleep Disorders as Core Symptoms of Depression,” Dialogues in Clinical Neuroscience 10, no. 3 (September 2008): 329-36.
601
Alexandra K. Gold and Louisa G. Sylvia, “The Role of Sleep in Bipolar Disorder,” Nature and Science of Sleep 8 (June 29, 2016): 207-14.
602
“Sleep and Mental Health,” Harvard Health Publishing.
603
Samuele Cortese et al., “Sleep and Alertness in Children with Attention-Deficit/ Hyperactivity Disorder: A Systematic Review of the Literature,” Sleep 29, no. 4 (2006): 504-11.
604
Kristine Yaffe et al., “Sleep-Disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older Women,” JAMA 306, no. 6 (2011): 613-19. Yo-El S. Ju, Brendan P. Lucey, and David M. Holtzman, “Sleep and Alzheimer Disease Pathology – A Bidirectional Relationship,” Nature Reviews Neurology 10, no. 2 (February 2014): 115-19. Wei-Pin Chang et al., “Sleep Apnea and the Risk of Dementia: A Population-Based 5-Year Follow-Up Study in Taiwan,” PLOS One 8 (October 24, 2013): e78655. Roxanne Sterniczuk et al., “Sleep Disturbance Is Associated with Incident Dementia and Mortality,” Current Alzheimer Research 10, no. 7 (September 2013): 767-75.
605
Tori Rodriguez, “Teenagers Who Don’t Get Enough Sleep at Higher Risk for Mental HealthProblems,” Scientific American, July 1, 2015, https://www.scientificamerican.com/article /teenagers-who-don-t-get-enough-sleep-at-higher-risk-for-mental-health-problems/.
606
R. Morgan Griffin, “The Health Risks of Shift Work,” WebMD, March 25, 2010, https://www.webmd.com/sleep-disorders/features/shift-work.
607
B. C. Tefft, “Acute Sleep Deprivation and Risk of Motor Vehicle Crash Involvement,” AAA Foundation for Traffic Safety, December 2016, https://aaafoundation.org/acute-sleep-deprivation-risk-motor-vehicle-crash-involvement/.
608
Gregory Belenky et al., “The Effects of Sleep Deprivation on Performance during Continuous Combat Operations,” в Food Components to Enhance Performance: An Evaluation of Potential Performance-Enhancing Food Components for Operational Rations, Institute of Medicine (US) Committee on Military Nutrition Research, ed. Bernadette M. Marriott (Washington, DC: National Academies Press, 1994), https://www.ncbi.nlm.nih.gov/books/NBK209071/.
609
Daniel F. Kripke, Robert D. Langer, and Lawrence E. Kline, “Hypnotics’ Association with Mortality or Cancer: A Matched Cohort Study,” BMJ Open 2, no. 1 (February 27, 2012): e000850.
610
“Serious Ambien Side Effects: Memory, Depression, and More,” American Addiction Centers, last updated July 25, 2019, https://americanaddictioncenters.org/ambien-treatment/side-effects.
611
Упомянутые социальные сети запрещены на территории РФ.
612
Daniel G. Amen, Memory Rescue (Carol Stream, IL: Tyndale, 2017), 248.
613
Daniel G. Amen and Tana Amen, The Brain Warrior’s Way (New York: New American Library, 2016), 203.
614
Там же, 205.
615
Там же, 203.
616
László Harmat, Johanna Takács, and Róbert Bódizs, “Music Improves Sleep Quality in Students,” Journal of Advanced Nursing 62, no. 3 (May 2008): 327-35.
617
Amen and Amen, Brain Warrior’s Way, 205.
618
Там же.
619
Namni Goel, Hyungsoo Kim, and Raymund P. Lao, “An Olfactory Stimulus Modifies Nighttime Sleep in Young Men and Women,” Chronobiology International 22, no. 5 (2005): 889–904. Mark Hardy, Michael D. Kirk-Smith, and David D. Stretch, “Replacement of Drug Treatment for Insomnia by Ambient Odour,” Lancet 346, no. 8976 (September 9, 1995): 701.
620
Амен, Д. Полюби свой мозг. Как превратить свои извилины из наезженной колеи в магистрали успеха. – Бомбора, 2019.
621
Gina Kolata, “Under New Guidelines, Millions More Americans Will Need to Lower Blood Pressure,” New York Times, November 13, 2017, https://www.nytimes.com/2017/11/13/health/blood-pressure-treatment-guidelines.html?_r=0. Susan Scutti, “Nearly Half of Americans Now Have High Blood Pressure, Based on New Guidelines,” Health, CNN, November 14, 2017, https://www.cnn.com/2017/11/13/health /new-blood-pressure-guidelines/index.html.
622
Penelope Elias et al., “Serum Cholesterol and Cognitive Performance in the Framingham Heart Study,” Psychosomatic Medicine 67, no. 1 (January/February 2005): 24–30.
623
M. M. Mielke et al., “High Total Cholesterol Levels in Late Life Associated with a Reduced Risk of Dementia,” Neurology 64, no. 10 (May 24, 2005): 1689-95. Annelies W. E. Weverling-Rijnsburger et al., “Total Cholesterol and Risk of Mortality in the Oldest Old,” Lancet 350, no. 9085 (October 18, 1997): 1119-23.
624
Амен, Д. Полюби свой мозг. Как превратить свои извилины из наезженной колеи в магистрали успеха. – Бомбора, 2019.
625
Амен, Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
626
Амен, Д. Загадки женского мозга. – Эксмо, 2014.
627
Амен, Д. Полюби свой мозг. Как превратить свои извилины из наезженной колеи в магистрали успеха. – Бомбора, 2019.
628
“Cancers Associated with Overweight and Obesity Make Up 40 Percent of Cancers Diagnosed in the United States,” CDC Newsroom, Centers for Disease Control and Prevention, last updated October 3, 2017, https://www.cdc.gov/media/releases/2017 /p1003-vs-cancer-obesity.html.
629
Амен, Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
630
T. S. Sathyanarayana Rao et al., “Understanding Nutrition, Depression and Mental Illnesses,” Indian Journal of Psychiatry 50, no. 2 (April – June 2008): 77–82.
631
Jerome Sarris et al., “Nutritional Medicine as Mainstream in Psychiatry,” Lancet 2, no. 3 (2015): 271-74.
632
Felice N. Jacka et al., “Western Diet Is Associated with a Smaller Hippocampus: A Longitudinal Investigation,” BMC Medicine 13 (September 8, 2015): 215.
633
Felice N. Jacka et al., “Dietary Patterns and Depressive Symptoms over Time: Examining the Relationships with Socioeconomic Position, Health Behaviours and Cardiovascular Risk,” PLOS One 9, no. 1 (January 29, 2014): e87657. Behnaz Shakersain et al., “Prudent Diet May Attenuate the Adverse Effects of Western Diet on Cognitive Decline,” Alzheimer’s and Dementia 12, no. 2 (February 2016): 100–109. Amber L. Howard et al., “ADHD Is Associated with a ‘Western’ Dietary Pattern in Adolescents,” Journal of Attention Disorders 15, no. 5 (July 2011): 403-11. Giovanni Tarantino, Vincenzo Citro, and Carmine Finelli, “Hype or Reality: Should Patients with Metabolic Syndrome-Related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?” Journal of Gastrointestinal and Liver Diseases 24, no. 3 (September 2015): 359-68.
634
National Center for Chronic Disease Prevention and Health Promotion, The Power of Prevention: Chronic Disease. the Public Health Challenge of the 21st Century, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2009, https://www.cdc.gov/chronicdisease/pdf/2009-Power-of-Prevention.pdf.
635
Maximus Berger et al., “Cross-Sectional Association of Seafood Consumption, Polyunsaturated Fatty Acids and Depressive Symptoms in Two Torres Strait Communities,” Nutritional Neuroscience, August 3, 2018, https://doi.org/10.1080/1028415X.2018.1504429.
636
Lawrence E. Armstrong et al., “Mild Dehydration Affects Mood in Healthy Young Women,” Journal of Nutrition 142, no. 2 (February 2012): 382-88 Matthew S. Ganio et al., “Mild Dehydration Impairs Cognitive Performance and Mood of Men,” British Journal of Nutrition 106, no. 10 (November 28, 2011): 1535-43.
637
Ana Adan, “Cognitive Performance and Dehydration,” Journal of the American College of Nutrition 31, no. 2 (2012): 71–78.
638
Kunio Nakamura et al., “Correlation between Brain Volume Change and T2 Relaxation Time Induced by Dehydration and Rehydration: Implications for Monitoring Atrophy in Clinical Studies,” NeuroImage: Clinical 6 (2014): 166-70.
639
Paul D. Lindseth et al., “Effects of Hydration on Cognitive Function of Pilots,” Military Medicine 178, no. 7 (July 2013): 792-98.
640
Daniel G. Amen and Tana Amen, The Brain Warrior’s Way (New York: New American Library, 2016), 113.
641
Rosebud O. Roberts et al., “Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia,” Journal of Alzheimer’s Disease 32, no. 2 (2012): 329-39.
642
Lenore Arab, Rong Guo, and David Elashoff, “Lower Depression Scores among Walnut Consumers in NHANES,” Nutrients 11, no. 2 (January 26, 2019): e275.
643
James E. Gangwisch et al., “High Glycemic Index Diet as a Risk Factor for Depression: Analyses from the Women’s Health Initiative,” American Journal of Clinical Nutrition 102, no. 2 (August 2015): 454-63.
644
Kara L. Breymeyer et al., “Subjective Mood and Energy Levels of Healthy Weight and Overweight/Obese Healthy Adults on High– and Low-Glycemic Load Experimental Diets,” Appetite 107 (December 1, 2016): 253-59.
645
Амен, Д. Полюби свой мозг. Как превратить свои извилины из наезженной колеи в магистрали успеха. – Бомбора, 2019.
646
Bayani Uttara et al., “Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options,” Current Neuropharmacology 7, no. 1 (March 2009): 65–74.
647
Gora Dadheech et al., “Evaluation of Antioxidant Deficit in Schizophrenia,” Indian Journal of Psychiatry 50, no. 1 (January – March 2008): 16–20.
648
Tao Liu et al., “A Meta-Analysis of Oxidative Stress Markers in Depression,” PLOS One 10, no. 10 (October 7, 2015): e0138904.
649
Medhavi Gautam et al., “Role of Antioxidants in Generalised Anxiety Disorder and Depression,” Indian Journal of Psychiatry 54, no. 3 (July – September 2012): 244-47.
650
См.: “List of Foods,” ORAC Database, accessed August 25, 2019, https://oracdatabase. com/list-of-foods/list-of-foods/. Цифры округлены.
651
University of Warwick, “Fruit and Veggies Give You the Feel-Good Factor,” ScienceDaily, July 10, 2016, https://www.sciencedaily.com/releases/2016/07/160710094239.htm.
652
Амен, Д. Измените свой мозг – изменится и жизнь! – Эксмо, 2009.
653
Amen and Amen, Brain Warrior’s Way, 142.
654
Lidy M. Pelsser et al., “A Randomised Controlled Trial into the Effects of Food on ADHD,” European Child and Adolescent Psychiatry 18, no. 1 (January 2009): 12–19.
655
Lidy M. Pelsser et al., “Effects of Food on Physical and Sleep Complaints in Children with ADHD: A Randomised Controlled Pilot Study,” European Journal of Pediatrics 169, no. 9 (September 2010): 1129-38.
656
Donna McCann et al., “Food Additives and Hyperactive Behavior in 3-Year-Old and 8/9-Year-Old Children in the Community: A Randomised, Double-Blinded, Placebo-Controlled Trial,” Lancet 370, no. 9598 (November 3, 2007): 1560-67.
657
Rachel B. Acton et al., “Added Sugar in the Packaged Foods and Beverages Available at a Major Canadian Retailer in 2015: A Descriptive Analysis,” CMAJ Open 5, no. 1 (January 12, 2017): e1-6.
658
Michelle Pearlman, Jon Obert, and Lisa Casey, “The Association between Artificial Sweeteners and Obesity,” Current Gastroenterology Reports 19, no. 12 (2017): 64.
659
Jessica R. Jackson et al., “Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity,” Psychiatric Quarterly 83, no. 1 (March 2012): 91-102.
660
Megan Anne Arroll, Lorraine Wilder, and James Neil, “Nutritional Interventions for the Adjunctive Treatment of Schizophrenia: A Brief Review,” Nutrition Journal 13 (September 16, 2014): 91. Elena Lionetti et al., “Gluten Psychosis: Confirmation of a New Clinical Entity,” Nutrients 7, no. 7 (July 8, 2015): 5532-39.
661
Helmut Niederhofer, “Association of Attention-Deficit/Hyperactivity Disorder and Celiac Disease: A Brief Report,” Primary Care Companion to CNS Disorders 13, no. 3 (2011): e1-31. Paul Whiteley et al., “The ScanBrit Randomised, Controlled, Single-Blind Study of a Gluten– and Casein-Free Dietary Intervention for Children with Autism Spectrum Disorders,” Nutritional Neuroscience 13, no. 2 (2010): 87-100 Antonio Di Sabatino et al., “Small Amounts of Gluten in Subjects with Suspected Nonceliac Gluten Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial,” Clinical Gastroenterology and Hepatology 13, no. 9 (September 2015): 1604-12.e3. S. L. Peters et al., “Randomised Clinical Trial: Gluten May Cause Depression in Subjects with Non-coeliac Gluten Sensitivity – An Exploratory Clinical Study,” Alimentary Pharmacology and Therapeutics 39, no. 10 (May 2014): 1104-12.
662
Eleanor Busby et al., “Mood Disorders and Gluten: It’s Not All in Your Mind! A Systematic Review with Meta-Analysis,” Nutrients 10, no. 11 (November 8, 2018): e1708.
663
Paola Bressan and Peter Kramer, “Bread and Other Edible Agents of Mental Disease,” Frontiers in Human Neuroscience 10 (March 29, 2016): 130.
664
Leo Pruimboom and Karin de Punder, “The Opioid Effects of Gluten Exorphins: Asymptomatic Celiac Disease,” Journal of Health, Population and Nutrition 33 (November 24, 2015): 24.
665
Bressan and Kramer, “Bread and Other Edible Agents,” 130.
666
P. Usai et al., “Frontal Cortical Perfusion Abnormalities Related to Gluten Intake and Associated Autoimmune Disease in Adult Coeliac Disease: 99mTc-ECD Brain SPECT Study,” Digestive and Liver Disease 36, no. 8 (August 2004): 513-18 A. De Santis et al., “Schizophrenic Symptoms and SPECT Abnormalities in a Coeliac Patient: Regression after a Gluten-Free Diet,” Journal of Internal Medicine 242, no. 5 (November 1997): 421-23.
667
Giovanni Addolorato et al., “Regional Cerebral Hypoperfusion in Patients with Celiac Disease,” American Journal of Medicine 116, no. 5 (March 1, 2004): 312-17 Maurizio Gabrielli et al., “Association between Migraine and Celiac Disease: Results from a Preliminary Case-Control and Therapeutic Study,” American Journal of Gastroenterology 98, no. 3 (March 2003): 625-29.
668
M. Hadjivassiliou et al., “Dietary Treatment of Gluten Ataxia,” Journal of Neurology, Neurosurgery and Psychiatry 74, no. 9 (September 2003): 1221-24.
669
F. C. Dohan et al., “Is Schizophrenia Rare if Grain Is Rare?” Biological Psychiatry 19, no. 3 (March 1984): 385-99.
670
F. C. Dohan and J. C. Grasberger, “Relapsed Schizophrenics: Earlier Discharge from the Hospital after Cereal-Free, Milk-Free Diet,” American Journal of Psychiatry 130, no. 6 (1973): 685-88.
671
Robin Mesnage et al., “Potential Toxic Effects of Glyphosate and Its Commercial Formulations below Regulatory Limits,” Food and Chemical Toxicology 84 (October 2015): 133-53.
672
K. R. Fluegge and K. R. Fluegge, “Glyphosate Use Predicts ADHD Hospital Discharges in the Healthcare Cost and Utilization Project Net (HCUPnet): A Two-Way Fixed-Effects Analysis,” PLOS One 10, no. 8 (August 21, 2015): e0133525, retraction August 21, 2015, PLOS One, https://doi.org/10.1371/journal.pone.0137489.
673
“15 Health Problems Linked to Monsanto’s Roundup,” EcoWatch, January 23, 2015, https://www.ecowatch.com/15-health-problems-linked-to-monsantos-roundup-1882002128.html.
674
Abdulaziz Farooq et al., “A Prospective Study of the Physiological and Neurobehavioral Effects of Ramadan Fasting in Preteen and Teenage Boys,” Journal of the Academy of Nutrition and Dietetics 115, no. 6 (June 2015): 889-97.
675
N. M. Hussin et al., “Efficacy of Fasting and Calorie Restriction (FCR) on Mood and Depression among Ageing Men,” Journal of Nutrition, Health and Aging 17, no. 8 (2013): 674-80. Kathryn C. Fitzgerald et al., “Effect of Intermittent vs. Daily Calorie Restriction on Changes in Weight and Patient-Reported Outcomes in People with Multiple Sclerosis,” Multiple Sclerosis and Related Disorders 23 (July 2018): 33–39.
676
Tatiana Moro et al., “Effects of Eight Weeks of Time-Restricted Feeding (16/8) on Basal Metabolism, Maximal Strength, Body Composition, Inflammation, and Cardiovascular Risk Factors in Resistance-Trained Males,” Journal of Translational Medicine 14, no. 1 (October 13, 2016): 290.
677
M. E. Faris et al., “Intermittent Fasting during Ramadan Attenuates Proinflammatory Cytokines and Immune Cells in Healthy Subjects,” Nutrition Research 32, no. 12 (December 2012): 947-55.
678
Andrea R. Vasconcelos et al., “Intermittent Fasting Attenuates LipopolysaccharideInduced Neuroinflammation and Memory Impairment,” Journal of Neuroinflammation 11 (May 6, 2014): 85.
679
Ben Spencer, “Why You Should NEVER Eat after 7pm: Late Night Meals ‘Increases the Risk of Heart Attack and Stroke,’” Daily Mail, August 31, 2016, https://www.dailymail.co.uk/health/article-3767231/Why-NEVER-eat-7pm-Late-night-meals-increases-risk-heart-attack-stroke.html.
680
Ameneh Madjd et al., “Beneficial Effect of High Energy Intake at Lunch Rather Than Dinner on Weight Loss in Healthy Obese Women in a Weight-Loss Program: A Randomized Clinical Trial,” American Journal of Clinical Nutrition 104, no. 4 (October 2016): 982-89.
681
публиковал сходный список в своей книге Memory Rescue (Tyndale, 2017), но данный список – это сокращенный вариант и в него вошли только те продукты, которые помогают или усугубляют проблемы с психическим здоровьем.